Journal Article
. 2009 Apr; 17(8):1453-64.
doi: 10.1038/mt.2009.83.

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

Michael C Milone 1 Jonathan D Fish  Carmine Carpenito  Richard G Carroll  Gwendolyn K Binder  David Teachey  Minu Samanta  Mehdi Lakhal  Brian Gloss  Gwenn Danet-Desnoyers  Dario Campana  James L Riley  Stephan A Grupp  Carl H June  
  • PMID: 19384291
  •     48 References
  •     506 citations


Persistence of T cells engineered with chimeric antigen receptors (CARs) has been a major barrier to use of these cells for molecularly targeted adoptive immunotherapy. To address this issue, we created a series of CARs that contain the T cell receptor-zeta (TCR-zeta) signal transduction domain with the CD28 and/or CD137 (4-1BB) intracellular domains in tandem. After short-term expansion, primary human T cells were subjected to lentiviral gene transfer, resulting in large numbers of cells with >85% CAR expression. In an immunodeficient mouse xenograft model of primary human pre-B-cell acute lymphoblastic leukemia, human T cells expressing anti-CD19 CARs containing CD137 exhibited the greatest antileukemic efficacy and prolonged (>6 months) survival in vivo, and were significantly more effective than cells expressing CARs containing TCR-zeta alone or CD28-zeta signaling receptors. We uncovered a previously unrecognized, antigen-independent effect of CARs expressing the CD137 cytoplasmic domain that likely contributes to the enhanced antileukemic efficacy and survival in tumor bearing mice. Furthermore, our studies revealed significant discrepancies between in vitro and in vivo surrogate measures of CAR efficacy. Together these results suggest that incorporation of the CD137 signaling domain in CARs should improve the persistence of CARs in the hematologic malignancies and hence maximize their antitumor activity.

TNF family ligands define niches for T cell memory.
Laurent Sabbagh, Laura M Snell, Tania H Watts.
Trends Immunol, 2007 Jun 29; 28(8). PMID: 17597006
The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways.
B A Irving, A Weiss.
Cell, 1991 Mar 08; 64(5). PMID: 1705867
Highly Cited.
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
Carmine Carpenito, Michael C Milone, +11 authors, Carl H June.
Proc Natl Acad Sci U S A, 2009 Feb 13; 106(9). PMID: 19211796    Free PMC article.
Highly Cited.
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
Michael Croft.
Nat Rev Immunol, 2003 Sep 17; 3(8). PMID: 12974476
Highly Cited. Review.
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
Michael H Kershaw, Jennifer A Westwood, +11 authors, Patrick Hwu.
Clin Cancer Res, 2006 Oct 26; 12(20 Pt 1). PMID: 17062687    Free PMC article.
Highly Cited.
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Nicole M Haynes, Joseph A Trapani, +6 authors, Phillip K Darcy.
Blood, 2002 Oct 18; 100(9). PMID: 12384413
A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells.
Hirotomo Shibaguchi, Nai-Xiang Luo, +5 authors, Masahide Kuroki.
Anticancer Res, 2007 Jan 02; 26(6A). PMID: 17195459
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Claudia M Kowolik, Max S Topp, +7 authors, Laurence J N Cooper.
Cancer Res, 2006 Nov 17; 66(22). PMID: 17108138
Highly Cited.
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.
Matthias T Stephan, Vladimir Ponomarev, +4 authors, Michel Sadelain.
Nat Med, 2007 Nov 21; 13(12). PMID: 18026115
Highly Cited.
CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes.
Richard V Parry, Catherine A Rumbley, +2 authors, James L Riley.
J Immunol, 2003 Jun 21; 171(1). PMID: 12816995
The role of stroma in immune recognition and destruction of well-established solid tumors.
Ping Yu, Donald A Rowley, Yang-Xin Fu, Hans Schreiber.
Curr Opin Immunol, 2006 Feb 07; 18(2). PMID: 16459066
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
Martin A Pule, Barbara Savoldo, +13 authors, Malcolm K Brenner.
Nat Med, 2008 Nov 04; 14(11). PMID: 18978797    Free PMC article.
Highly Cited.
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.
David T Teachey, Cecilia Sheen, +9 authors, Stephan A Grupp.
Blood, 2008 Jun 12; 112(5). PMID: 18544682    Free PMC article.
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.
Renier J Brentjens, Jean-Baptiste Latouche, +8 authors, Michel Sadelain.
Nat Med, 2003 Feb 13; 9(3). PMID: 12579196
Highly Cited.
Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Terence P F Gade, Waleed Hassen, +16 authors, Michel Sadelain.
Cancer Res, 2005 Oct 06; 65(19). PMID: 16204083
A third-generation lentivirus vector with a conditional packaging system.
T Dull, R Zufferey, +4 authors, L Naldini.
J Virol, 1998 Oct 10; 72(11). PMID: 9765382    Free PMC article.
Highly Cited.
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
John Maher, Renier J Brentjens, +2 authors, Michel Sadelain.
Nat Biotechnol, 2001 Dec 26; 20(1). PMID: 11753365
Highly Cited.
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Brian G Till, Michael C Jensen, +13 authors, Oliver W Press.
Blood, 2008 May 30; 112(6). PMID: 18509084    Free PMC article.
Highly Cited.
CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail.
I Stamenkovic, B Seed.
J Exp Med, 1988 Sep 01; 168(3). PMID: 2459292    Free PMC article.
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes.
Attilio Bondanza, Veronica Valtolina, +11 authors, Chiara Bonini.
Blood, 2005 Nov 19; 107(5). PMID: 16293601
Regulated expression of telomerase activity in human T lymphocyte development and activation.
N P Weng, B L Levine, C H June, R J Hodes.
J Exp Med, 1996 Jun 01; 183(6). PMID: 8676067    Free PMC article.
Highly Cited.
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.
Steven G Deeks, Bridget Wagner, +11 authors, Kristen M Hege.
Mol Ther, 2002 May 25; 5(6). PMID: 12027564
Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.
Helene M Finney, Arne N Akbar, Alastair D G Lawson.
J Immunol, 2003 Dec 23; 172(1). PMID: 14688315
Highly Cited.
Enhanced transgene expression in quiescent and activated human CD8+ T cells.
Laurence J N Cooper, Max S Topp, +4 authors, Philip D Greenberg.
Hum Gene Ther, 2004 Jul 10; 15(7). PMID: 15242525
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.
Megan M Suhoski, Tatiana N Golovina, +6 authors, Carl H June.
Mol Ther, 2007 Mar 22; 15(5). PMID: 17375070    Free PMC article.
Highly Cited.
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.
C Imai, K Mihara, +4 authors, D Campana.
Leukemia, 2004 Feb 13; 18(4). PMID: 14961035
Highly Cited.
Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.
H M Finney, A D Lawson, C R Bebbington, A N Weir.
J Immunol, 1998 Sep 22; 161(6). PMID: 9743337
Highly Cited.
Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load.
Laurent M Humeau, Gwendolyn K Binder, +11 authors, Boro Dropulic.
Mol Ther, 2004 Jun 15; 9(6). PMID: 15194057
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
Martin A Pulè, Karin C Straathof, +3 authors, Malcolm K Brenner.
Mol Ther, 2005 Jun 28; 12(5). PMID: 15979412
Highly Cited.
Molecular portraits of B cell lineage commitment.
Markus Müschen, Sanggyu Lee, +7 authors, San Ming Wang.
Proc Natl Acad Sci U S A, 2002 Jul 18; 99(15). PMID: 12119411    Free PMC article.
Gene transfer in humans using a conditionally replicating lentiviral vector.
Bruce L Levine, Laurent M Humeau, +10 authors, Carl H June.
Proc Natl Acad Sci U S A, 2006 Nov 09; 103(46). PMID: 17090675    Free PMC article.
Highly Cited.
Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.
B L Levine, W B Bernstein, +4 authors, C H June.
J Immunol, 1998 Apr 29; 159(12). PMID: 9550389
Highly Cited.
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.
Jinjuan Wang, Michael Jensen, +11 authors, Oliver W Press.
Hum Gene Ther, 2007 Aug 10; 18(8). PMID: 17685852
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.
W W Shuford, K Klussman, +11 authors, R S Mittler.
J Exp Med, 1997 Jul 07; 186(1). PMID: 9206996    Free PMC article.
Highly Cited.
CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype.
Yuwen Zhu, Gefeng Zhu, +2 authors, Lieping Chen.
Blood, 2007 Jan 25; 109(11). PMID: 17244673    Free PMC article.
Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes.
T L Geiger, P Nguyen, D Leitenberg, R A Flavell.
Blood, 2001 Oct 06; 98(8). PMID: 11588032
Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging.
N P Weng, L D Palmer, +3 authors, R J Hodes.
Immunol Rev, 1998 Feb 26; 160. PMID: 9476664
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.
I Melero, W W Shuford, +5 authors, L Chen.
Nat Med, 1997 Jun 01; 3(6). PMID: 9176498
Highly Cited.
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
Julie R Park, David L Digiusto, +8 authors, Michael C Jensen.
Mol Ther, 2007 Feb 15; 15(4). PMID: 17299405
Highly Cited.
4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1.
Hyeon-Woo Lee, Kyung-Ok Nam, Su-Jung Park, Byoung S Kwon.
Eur J Immunol, 2003 Jul 29; 33(8). PMID: 12884287
IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival.
Gayle Pulle, Mariana Vidric, Tania H Watts.
J Immunol, 2006 Feb 24; 176(5). PMID: 16493029
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Z Eshhar, T Waks, G Gross, D G Schindler.
Proc Natl Acad Sci U S A, 1993 Jan 15; 90(2). PMID: 8421711    Free PMC article.
Highly Cited.
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation.
Dinorah Friedmann-Morvinski, Alain Bendavid, +2 authors, Zelig Eshhar.
Blood, 2005 Jan 01; 105(8). PMID: 15626734
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.
David T Teachey, Dana A Obzut, +6 authors, Stephan A Grupp.
Blood, 2005 Oct 01; 107(3). PMID: 16195324    Free PMC article.
Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
A Hombach, A Wieczarkowiecz, +5 authors, H Abken.
J Immunol, 2001 Nov 21; 167(11). PMID: 11714771
T cells for suicide gene therapy: activation, functionality and clinical relevance.
Gabriele Hollatz, M Grez, +8 authors, U Koehl.
J Immunol Methods, 2007 Dec 25; 331(1-2). PMID: 18155021
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1.
Hyeon-Woo Lee, Su-Jung Park, +3 authors, Byoung S Kwon.
J Immunol, 2002 Oct 23; 169(9). PMID: 12391199
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
Renier J Brentjens, Elmer Santos, +6 authors, Michel Sadelain.
Clin Cancer Res, 2007 Sep 15; 13(18 Pt 1). PMID: 17855649
Highly Cited.
Persuading natural killer cells to eliminate bad B cells.
Laurence J N Cooper.
Clin Cancer Res, 2009 Jul 30; 15(15). PMID: 19638468    Free PMC article.
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".
Gianpietro Dotti, Barbara Savoldo, Malcolm Brenner.
Hum Gene Ther, 2009 Aug 26; 20(11). PMID: 19702437    Free PMC article.
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.
Syam Tammana, Xin Huang, +7 authors, Xianzheng Zhou.
Hum Gene Ther, 2009 Sep 02; 21(1). PMID: 19719389    Free PMC article.
Treatment of lymphoma with adoptively transferred T cells.
Brian G Till, Oliver W Press.
Expert Opin Biol Ther, 2009 Sep 03; 9(11). PMID: 19723016    Free PMC article.
Immunotherapy of human cancers using gene modified T lymphocytes.
Juan F Vera, Malcolm K Brenner, Gianpietro Dotti.
Curr Gene Ther, 2009 Oct 29; 9(5). PMID: 19860654    Free PMC article.
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
Richard A Morgan, James C Yang, +3 authors, Steven A Rosenberg.
Mol Ther, 2010 Feb 25; 18(4). PMID: 20179677    Free PMC article.
Highly Cited.
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.
Scott E James, Philip D Greenberg, +7 authors, Oliver W Press.
J Immunol, 2010 Mar 12; 184(8). PMID: 20220093    Free PMC article.
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.
Jae H Park, Renier J Brentjens.
Discov Med, 2010 Apr 29; 9(47). PMID: 20423671    Free PMC article.
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.
Jeff K Davies, Harjeet Singh, +7 authors, Laurence J N Cooper.
Cancer Res, 2010 Apr 29; 70(10). PMID: 20424114    Free PMC article.
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.
V Hoyos, B Savoldo, +7 authors, G Dotti.
Leukemia, 2010 Apr 30; 24(6). PMID: 20428207    Free PMC article.
Highly Cited.
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
Bipulendu Jena, Gianpietro Dotti, Laurence J N Cooper.
Blood, 2010 May 05; 116(7). PMID: 20439624    Free PMC article.
Highly Cited. Review.
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.
Marc Cartellieri, Michael Bachmann, +5 authors, Marc Schmitz.
J Biomed Biotechnol, 2010 May 15; 2010. PMID: 20467460    Free PMC article.
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.
Gloria H Y Lin, Yuanqing Liu, +3 authors, Tania H Watts.
PLoS One, 2010 Jun 15; 5(6). PMID: 20543982    Free PMC article.
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
James N Kochenderfer, Zhiya Yu, +2 authors, Steven A Rosenberg.
Blood, 2010 Jul 16; 116(19). PMID: 20631379    Free PMC article.
Highly Cited.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
James N Kochenderfer, Wyndham H Wilson, +9 authors, Steven A Rosenberg.
Blood, 2010 Jul 30; 116(20). PMID: 20668228    Free PMC article.
Highly Cited.
Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.
Patrick J Hanley, Conrad Russell Cruz, Elizabeth J Shpall, Catherine M Bollard.
Cytotherapy, 2010 Sep 08; 12(6). PMID: 20818913    Free PMC article.
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Yangbing Zhao, Edmund Moon, +9 authors, Carl H June.
Cancer Res, 2010 Oct 12; 70(22). PMID: 20926399    Free PMC article.
Highly Cited.
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.
Dhanalakshmi Chinnasamy, Zhiya Yu, +6 authors, Steven A Rosenberg.
J Clin Invest, 2010 Oct 28; 120(11). PMID: 20978347    Free PMC article.
Biology by design: from top to bottom and back.
Brian R Fritz, Laura E Timmerman, +2 authors, Michael C Jewett.
J Biomed Biotechnol, 2010 Nov 06; 2010. PMID: 21052559    Free PMC article.
Cellular immunotherapy for high-grade glioma.
K H Chow, Stephen Gottschalk.
Immunotherapy, 2011 Mar 15; 3(3). PMID: 21395383    Free PMC article.
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
Greta Maria Paola Giordano Attianese, Virna Marin, +11 authors, Ettore Biagi.
Blood, 2011 Mar 17; 117(18). PMID: 21406718    Free PMC article.
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.
Carlos A Ramos, Gianpietro Dotti.
Expert Opin Biol Ther, 2011 Apr 06; 11(7). PMID: 21463133    Free PMC article.
Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice.
Ana Caterina Parente-Pereira, Jerome Burnet, +8 authors, John Maher.
J Clin Immunol, 2011 Apr 21; 31(4). PMID: 21505816
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
De-Gang Song, Qunrui Ye, +7 authors, Daniel J Powell.
Cancer Res, 2011 May 07; 71(13). PMID: 21546571    Free PMC article.
Highly Cited.
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
Edmund K Moon, Carmine Carpenito, +7 authors, Steven M Albelda.
Clin Cancer Res, 2011 May 26; 17(14). PMID: 21610146    Free PMC article.
Highly Cited.
Chimeric Antigen Receptor Therapy for B-cell Malignancies.
David L Porter, Michael Kalos, +2 authors, Carl June.
J Cancer, 2011 Jul 01; 2. PMID: 21716851    Free PMC article.
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
David L Porter, Bruce L Levine, +2 authors, Carl H June.
N Engl J Med, 2011 Aug 13; 365(8). PMID: 21830940    Free PMC article.
Highly Cited.
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
Michael Kalos, Bruce L Levine, +4 authors, Carl H June.
Sci Transl Med, 2011 Aug 13; 3(95). PMID: 21832238    Free PMC article.
Highly Cited.
Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.
Philipp Koehler, Patrick Schmidt, +2 authors, Hinrich Abken.
Adv Hematol, 2011 Aug 13; 2012. PMID: 21837241    Free PMC article.
Treatment of advanced leukemia in mice with mRNA engineered T cells.
David M Barrett, Yangbing Zhao, +6 authors, Stephan A Grupp.
Hum Gene Ther, 2011 Aug 16; 22(12). PMID: 21838572    Free PMC article.
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
Renier J Brentjens, Isabelle Rivière, +24 authors, Michel Sadelain.
Blood, 2011 Aug 19; 118(18). PMID: 21849486    Free PMC article.
Highly Cited.
Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.
David M Barrett, Alix E Seif, +5 authors, Gregor S D Reid.
Blood, 2011 Aug 23; 118(15). PMID: 21856863    Free PMC article.
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
Seitaro Terakura, Tori N Yamamoto, +3 authors, Stanley R Riddell.
Blood, 2011 Oct 28; 119(1). PMID: 22031866    Free PMC article.
Highly Cited.
Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers.
Steven A Rosenberg, James N Kochenderfer.
Mol Ther, 2011 Nov 05; 19(11). PMID: 22051601    Free PMC article.
Cellular therapies in acute lymphoblastic leukemia.
Jae H Park, Craig Sauter, Renier Brentjens.
Hematol Oncol Clin North Am, 2011 Nov 19; 25(6). PMID: 22093587    Free PMC article.
Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
Evripidis Lanitis, Mathilde Poussin, +4 authors, Daniel J Powell.
Mol Ther, 2011 Dec 01; 20(3). PMID: 22127019    Free PMC article.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
James N Kochenderfer, Mark E Dudley, +15 authors, Steven A Rosenberg.
Blood, 2011 Dec 14; 119(12). PMID: 22160384    Free PMC article.
Highly Cited.
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity.
Partow Kebriaei, Susan S Kelly, +5 authors, Laurence J N Cooper.
Front Biosci (Schol Ed), 2011 Dec 29; 4(2). PMID: 22202074    Free PMC article.
Immune reconstitution in chronic lymphocytic leukemia.
John C Riches, Alan G Ramsay, John G Gribben.
Curr Hematol Malig Rep, 2012 Jan 11; 7(1). PMID: 22231031    Free PMC article.
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
Kevin J Curran, Hollie J Pegram, Renier J Brentjens.
J Gene Med, 2012 Jan 21; 14(6). PMID: 22262649    Free PMC article.
Highly Cited. Review.
Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.
Stephen E Wright, Kathleen A Rewers-Felkins, +6 authors, William Robinson.
J Immunother, 2012 Feb 07; 35(2). PMID: 22306908    Free PMC article.
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Brian G Till, Michael C Jensen, +12 authors, Oliver W Press.
Blood, 2012 Feb 07; 119(17). PMID: 22308288    Free PMC article.
Highly Cited.
Armed and accurate: engineering cytotoxic T cells for eradication of leukemia.
Marko Radic.
BMC Biotechnol, 2012 Feb 10; 12. PMID: 22316161    Free PMC article.
TCR affinity and specificity requirements for human regulatory T-cell function.
Gabriela Plesa, Lingjie Zheng, +10 authors, James L Riley.
Blood, 2012 Feb 10; 119(15). PMID: 22318202    Free PMC article.
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.
Daniel W Lee, David M Barrett, +2 authors, Stephan A Grupp.
Clin Cancer Res, 2012 May 17; 18(10). PMID: 22589486    Free PMC article.
Current translational and clinical practices in hematopoietic cell and gene therapy.
David L Digiusto, Hans-Peter Kiem.
Cytotherapy, 2012 Jul 18; 14(7). PMID: 22799276    Free PMC article.
CD19 as an attractive target for antibody-based therapy.
Ohad Hammer.
MAbs, 2012 Jul 24; 4(5). PMID: 22820352    Free PMC article.
Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation.
Naoki Kunii, Yangbing Zhao, +6 authors, Carl H June.
Hum Gene Ther, 2012 Sep 25; 24(1). PMID: 22998346    Free PMC article.
Mitosis-targeted anti-cancer therapies: where they stand.
K-S Chan, C-G Koh, H-Y Li.
Cell Death Dis, 2012 Oct 19; 3. PMID: 23076219    Free PMC article.
Highly Cited. Review.
Genetically engineered T cells for the treatment of cancer.
M Essand, A S I Loskog.
J Intern Med, 2012 Dec 04; 273(2). PMID: 23198862    Free PMC article.
CARs in chronic lymphocytic leukemia -- ready to drive.
Chitra Hosing, Partow Kebriaei, +3 authors, Elizabeth Shpall.
Curr Hematol Malig Rep, 2012 Dec 12; 8(1). PMID: 23225251    Free PMC article.
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
Renier J Brentjens, Kevin J Curran.
Hematology Am Soc Hematol Educ Program, 2012 Dec 13; 2012. PMID: 23233573    Free PMC article.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Waleed Haso, Daniel W Lee, +10 authors, Rimas J Orentas.
Blood, 2012 Dec 18; 121(7). PMID: 23243285    Free PMC article.
Highly Cited.
Children's Oncology Group's 2013 blueprint for research: stem cell transplantation.
Stephan A Grupp, Christopher C Dvorak, +5 authors, COG Stem Cell Transplant Scientific Committee.
Pediatr Blood Cancer, 2012 Dec 21; 60(6). PMID: 23255402    Free PMC article.
How do CARs work?: Early insights from recent clinical studies targeting CD19.
Marco L Davila, Renier Brentjens, +2 authors, Michel Sadelain.
Oncoimmunology, 2012 Dec 25; 1(9). PMID: 23264903    Free PMC article.
Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.
Mohamed-Rachid Boulassel, Ahmed Galal.
Sultan Qaboos Univ Med J, 2012 Dec 28; 12(3). PMID: 23269948    Free PMC article.
Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
De-Gang Song, Qunrui Ye, +3 authors, Daniel J Powell.
Hum Gene Ther, 2013 Jan 10; 24(3). PMID: 23297870    Free PMC article.
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.
John Maher.
ISRN Oncol, 2013 Jan 11; 2012. PMID: 23304553    Free PMC article.
Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.
Francesca Giannoni, Cinnamon L Hardee, +13 authors, Donald B Kohn.
Mol Ther, 2013 Feb 06; 21(5). PMID: 23380815    Free PMC article.
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.
Renier J Brentjens, Marco L Davila, +22 authors, Michel Sadelain.
Sci Transl Med, 2013 Mar 22; 5(177). PMID: 23515080    Free PMC article.
Highly Cited.
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A Grupp, Michael Kalos, +10 authors, Carl H June.
N Engl J Med, 2013 Mar 27; 368(16). PMID: 23527958    Free PMC article.
Highly Cited.
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
James N Kochenderfer, Steven A Rosenberg.
Nat Rev Clin Oncol, 2013 Apr 03; 10(5). PMID: 23546520    Free PMC article.
Highly Cited. Review.
The basic principles of chimeric antigen receptor design.
Michel Sadelain, Renier Brentjens, Isabelle Rivière.
Cancer Discov, 2013 Apr 04; 3(4). PMID: 23550147    Free PMC article.
Highly Cited. Review.
Cellular therapy following allogeneic stem-cell transplantation.
Alison Rager, David L Porter.
Ther Adv Hematol, 2011 Dec 01; 2(6). PMID: 23556106    Free PMC article.
Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?
Marco L Davila, Renier Brentjens.
Hematol Oncol Clin North Am, 2013 Apr 09; 27(2). PMID: 23561477    Free PMC article.
Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.
Matthew J Riese, Liang-Chuan S Wang, +5 authors, Steven M Albelda.
Cancer Res, 2013 Apr 12; 73(12). PMID: 23576561    Free PMC article.
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
Michael Hudecek, Maria-Teresa Lupo-Stanghellini, +4 authors, Stanley R Riddell.
Clin Cancer Res, 2013 Apr 27; 19(12). PMID: 23620405    Free PMC article.
Highly Cited.
Harnessing autophagy for cell fate control gene therapy.
Tania C Felizardo, Jason Foley, +4 authors, Daniel H Fowler.
Autophagy, 2013 May 02; 9(7). PMID: 23633667    Free PMC article.
The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.
C Arber, H Abhyankar, +4 authors, B Savoldo.
Gene Ther, 2013 May 24; 20(9). PMID: 23698740    Free PMC article.
Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle.
Andreas A Hombach, Hinrich Abken.
Front Immunol, 2013 Jun 14; 4. PMID: 23761793    Free PMC article.
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.
Ethan Q Han, Xiu-ling Li, +2 authors, Shuang-yin Han.
J Hematol Oncol, 2013 Jul 09; 6. PMID: 23829929    Free PMC article.
CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
Tomonori Tsukahara, Ken Ohmine, +13 authors, Keiya Ozawa.
Biochem Biophys Res Commun, 2013 Jul 23; 438(1). PMID: 23872144    Free PMC article.
Gene-engineered T cells for cancer therapy.
Michael H Kershaw, Jennifer A Westwood, Phillip K Darcy.
Nat Rev Cancer, 2013 Jul 25; 13(8). PMID: 23880905
Highly Cited. Review.
Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.
David M Barrett, Xiaojun Liu, +3 authors, Yangbing Zhao.
Hum Gene Ther, 2013 Jul 26; 24(8). PMID: 23883116    Free PMC article.
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Armen Mardiros, Cedric Dos Santos, +14 authors, Stephen J Forman.
Blood, 2013 Sep 14; 122(18). PMID: 24030378    Free PMC article.
Highly Cited.
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.
Bryan D Choi, Carter M Suryadevara, +4 authors, John H Sampson.
J Clin Neurosci, 2013 Sep 24; 21(1). PMID: 24054399    Free PMC article.
Mouse models in bone marrow transplantation and adoptive cellular therapy.
Caroline Arber, Malcolm K Brenner, Pavan Reddy.
Semin Hematol, 2013 Nov 13; 50(2). PMID: 24216170    Free PMC article.
Engineered T cells for cancer treatment.
Usanarat Anurathapan, Ann M Leen, Malcolm K Brenner, Juan F Vera.
Cytotherapy, 2013 Nov 19; 16(6). PMID: 24239105    Free PMC article.
Chimeric antigen receptor therapy for cancer.
David M Barrett, Nathan Singh, +2 authors, Carl H June.
Annu Rev Med, 2013 Nov 28; 65. PMID: 24274181    Free PMC article.
Highly Cited. Review.
Design and development of therapies using chimeric antigen receptor-expressing T cells.
Gianpietro Dotti, Stephen Gottschalk, Barbara Savoldo, Malcolm K Brenner.
Immunol Rev, 2013 Dec 18; 257(1). PMID: 24329793    Free PMC article.
Highly Cited. Review.
Hematopoietic stem cells for cancer immunotherapy.
Eric Gschweng, Satiro De Oliveira, Donald B Kohn.
Immunol Rev, 2013 Dec 18; 257(1). PMID: 24329801    Free PMC article.
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
John H Sampson, Bryan D Choi, +12 authors, Laura A Johnson.
Clin Cancer Res, 2013 Dec 20; 20(4). PMID: 24352643    Free PMC article.
Highly Cited.
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.
Lihua E Budde, Carolina Berger, +9 authors, Oliver W Press.
PLoS One, 2013 Dec 21; 8(12). PMID: 24358223    Free PMC article.
Highly Cited.
Toxicity management for patients receiving novel T-cell engaging therapies.
David M Barrett, David T Teachey, Stephan A Grupp.
Curr Opin Pediatr, 2013 Dec 24; 26(1). PMID: 24362408    Free PMC article.
Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Evripidis Lanitis, Mathilde Poussin, +4 authors, Daniel J Powell.
Cancer Immunol Res, 2014 Jan 11; 1(1). PMID: 24409448    Free PMC article.
Highly Cited.
Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.
David M Barrett, Nathan Singh, +4 authors, Yangbing Zhao.
Cytotherapy, 2014 Jan 21; 16(5). PMID: 24439255    Free PMC article.
Driving CAR-based T-cell therapy to success.
Bipulendu Jena, Judy S Moyes, Helen Huls, Laurence J N Cooper.
Curr Hematol Malig Rep, 2014 Feb 04; 9(1). PMID: 24488441    Free PMC article.
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Marco L Davila, Isabelle Riviere, +29 authors, Renier Brentjens.
Sci Transl Med, 2014 Feb 21; 6(224). PMID: 24553386    Free PMC article.
Highly Cited.
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.
Marcela V Maus, Stephan A Grupp, David L Porter, Carl H June.
Blood, 2014 Mar 01; 123(17). PMID: 24578504    Free PMC article.
Highly Cited. Review.
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
Saar Gill, Sarah K Tasian, +9 authors, Michael Kalos.
Blood, 2014 Mar 07; 123(15). PMID: 24596416    Free PMC article.
Highly Cited.
Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Shannon L Maude, David Barrett, David T Teachey, Stephan A Grupp.
Cancer J, 2014 Mar 29; 20(2). PMID: 24667956    Free PMC article.
Highly Cited. Review.
A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells.
Marc Cartellieri, Stefanie Koristka, +12 authors, Michael P Bachmann.
PLoS One, 2014 Apr 05; 9(4). PMID: 24699869    Free PMC article.
Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.
Minhtran Charlotte Ngo, Jun Ando, +9 authors, Cliona M Rooney.
J Immunother, 2014 Apr 10; 37(4). PMID: 24714353    Free PMC article.
Cell transfer therapy for cancer: past, present, and future.
Xiaoling Qian, Xian Wang, Hongchuan Jin.
J Immunol Res, 2014 Apr 18; 2014. PMID: 24741604    Free PMC article.
An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.
Cécile Badoual, Pierre-Louis Bastier, +2 authors, Eric Tartour.
Oncoimmunology, 2014 Apr 23; 2(11). PMID: 24753987    Free PMC article.
Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
Liang-Chuan S Wang, Albert Lo, +11 authors, Steven M Albelda.
Cancer Immunol Res, 2014 Apr 30; 2(2). PMID: 24778279    Free PMC article.
Highly Cited.
T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Simone Krebs, Kevin K H Chow, +5 authors, Stephen Gottschalk.
Cytotherapy, 2014 May 21; 16(8). PMID: 24841514    Free PMC article.
Progress and prospects for engineered T cell therapies.
Waseem Qasim, Adrian J Thrasher.
Br J Haematol, 2014 Jun 18; 166(6). PMID: 24935654    Free PMC article.
Th17 cells in cancer: the ultimate identity crisis.
Stefanie R Bailey, Michelle H Nelson, +3 authors, Chrystal M Paulos.
Front Immunol, 2014 Jul 06; 5. PMID: 24987392    Free PMC article.
Highly Cited. Review.
A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.
Jennifer D Stone, Daniel T Harris, +4 authors, David M Kranz.
Cancer Immunol Immunother, 2014 Aug 02; 63(11). PMID: 25082071    Free PMC article.
Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Nathan Singh, Xiaojun Liu, +5 authors, Yangbing Zhao.
Cancer Immunol Res, 2014 Aug 12; 2(11). PMID: 25104548    Free PMC article.
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
James N Kochenderfer, Mark E Dudley, +23 authors, Steven A Rosenberg.
J Clin Oncol, 2014 Aug 27; 33(6). PMID: 25154820    Free PMC article.
Highly Cited.
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
Michael Hudecek, Daniel Sommermeyer, +5 authors, Stanley R Riddell.
Cancer Immunol Res, 2014 Sep 13; 3(2). PMID: 25212991    Free PMC article.
Highly Cited.
Toward synthetic biology with engineered T cells: a long journey just begun.
Carl H June.
Hum Gene Ther, 2014 Sep 23; 25(9). PMID: 25244569    Free PMC article.
PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models.
Gaia Zuccolotto, Giulio Fracasso, +8 authors, Antonio Rosato.
PLoS One, 2014 Oct 04; 9(10). PMID: 25279468    Free PMC article.
Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis.
Fu-Nan Cho, Tsung-Hsien Chang, +9 authors, Yu-Hsiang Chang.
PLoS One, 2014 Oct 15; 9(10). PMID: 25313995    Free PMC article.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, +16 authors, Stephan A Grupp.
N Engl J Med, 2014 Oct 16; 371(16). PMID: 25317870    Free PMC article.
Highly Cited.
Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy.
Mahesh Jonnalagadda, Armen Mardiros, +10 authors, Christine E Brown.
Mol Ther, 2014 Nov 05; 23(4). PMID: 25366031    Free PMC article.
An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.
Yair Tal, Shlomo Yaakobi, +4 authors, Cyrille J Cohen.
Oncotarget, 2014 Nov 29; 5(21). PMID: 25431955    Free PMC article.
CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Mustafa Diken, Sebastian Boegel, +6 authors, Sebastian Kreiter.
Hum Vaccin Immunother, 2014 Dec 09; 10(10). PMID: 25483671    Free PMC article.
Clinical application of genetically modified T cells in cancer therapy.
Michael H Kershaw, Jennifer A Westwood, Clare Y Slaney, Phillip K Darcy.
Clin Transl Immunology, 2014 Dec 17; 3(5). PMID: 25505964    Free PMC article.
Novel immunotherapies for hematologic malignancies.
Michelle H Nelson, Chrystal M Paulos.
Immunol Rev, 2014 Dec 17; 263(1). PMID: 25510273    Free PMC article.
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.
Matthew J Frigault, Jihyun Lee, +16 authors, Carl H June.
Cancer Immunol Res, 2015 Jan 21; 3(4). PMID: 25600436    Free PMC article.
Highly Cited.
Designing chimeric antigen receptors to effectively and safely target tumors.
Michael C Jensen, Stanley R Riddell.
Curr Opin Immunol, 2015 Jan 27; 33. PMID: 25621840    Free PMC article.
Highly Cited. Review.
Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.
Diana C G Bouhassira, Joshua J Thompson, Marco L Davila.
Expert Opin Biol Ther, 2015 Feb 11; 15(3). PMID: 25666545    Free PMC article.
Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.
B L Levine.
Cancer Gene Ther, 2015 Feb 14; 22(2). PMID: 25675873
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
Laura A Johnson, John Scholler, +26 authors, Marcela V Maus.
Sci Transl Med, 2015 Feb 20; 7(275). PMID: 25696001    Free PMC article.
Highly Cited.
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
S S Kenderian, M Ruella, +9 authors, S Gill.
Leukemia, 2015 Feb 28; 29(8). PMID: 25721896    Free PMC article.
Highly Cited.
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Nabil Ahmed, Vita S Brawley, +23 authors, Stephen Gottschalk.
J Clin Oncol, 2015 Mar 25; 33(15). PMID: 25800760    Free PMC article.
Highly Cited.
Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Victoria Hillerdal, Magnus Essand.
BioDrugs, 2015 Apr 11; 29(2). PMID: 25859858    Free PMC article.
Engineering T Cells to Functionally Cure HIV-1 Infection.
Rachel S Leibman, James L Riley.
Mol Ther, 2015 Apr 22; 23(7). PMID: 25896251    Free PMC article.
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Adrienne H Long, Waleed M Haso, +12 authors, Crystal L Mackall.
Nat Med, 2015 May 06; 21(6). PMID: 25939063    Free PMC article.
Highly Cited.
Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.
Enxiu Wang, Liang-Chuan Wang, +12 authors, Michael C Milone.
Cancer Immunol Res, 2015 May 06; 3(7). PMID: 25941351    Free PMC article.
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.
Shannon L Maude, David T Teachey, David L Porter, Stephan A Grupp.
Blood, 2015 May 23; 125(26). PMID: 25999455    Free PMC article.
Highly Cited. Review.
Pre-TCRα supports CD3-dependent reactivation and expansion of TCRα-deficient primary human T-cells.
Román Galetto, Celine Lebuhotel, +4 authors, Andrew Scharenberg.
Mol Ther Methods Clin Dev, 2014 Jan 01; 1. PMID: 26015965    Free PMC article.
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Bettina Weigelin, Elixabet Bolaños, +10 authors, Ignacio Melero.
Proc Natl Acad Sci U S A, 2015 Jun 03; 112(24). PMID: 26034288    Free PMC article.
The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.
Frank Cichocki, Michael R Verneris, +8 authors, Jeffrey S Miller.
Curr Top Microbiol Immunol, 2015 Jun 04; 395. PMID: 26037048    Free PMC article.
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.
Haiying Qin, Monica Cho, +15 authors, Terry J Fry.
Blood, 2015 Jun 05; 126(5). PMID: 26041741    Free PMC article.
Adoptive T-cell therapy for Leukemia.
Haven R Garber, Asma Mirza, Elizabeth A Mittendorf, Gheath Alatrash.
Mol Cell Ther, 2014 Jan 01; 2. PMID: 26056592    Free PMC article.
A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.
De-Gang Song, Qunrui Ye, +3 authors, Daniel J Powell.
Oncotarget, 2015 Jun 24; 6(25). PMID: 26101914    Free PMC article.
T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
Heather VanSeggelen, Joanne A Hammill, +6 authors, Jonathan L Bramson.
Mol Ther, 2015 Jul 01; 23(10). PMID: 26122933    Free PMC article.
The pharmacology of second-generation chimeric antigen receptors.
Sjoukje J C van der Stegen, Mohamad Hamieh, Michel Sadelain.
Nat Rev Drug Discov, 2015 Jul 02; 14(7). PMID: 26129802    Free PMC article.
Highly Cited. Review.
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street.
David M Barrett, Stephan A Grupp, Carl H June.
J Immunol, 2015 Jul 19; 195(3). PMID: 26188068    Free PMC article.
Highly Cited. Review.
Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.
Fei Chen, Chuming Fan, +6 authors, Xun Lai.
Med Sci Monit, 2015 Jul 22; 21. PMID: 26195067    Free PMC article.
Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
N Epperla, T S Fenske, H M Lazarus, M Hamadani.
Bone Marrow Transplant, 2015 Aug 19; 50(11). PMID: 26281033
CAR therapy: the CD19 paradigm.
Michel Sadelain.
J Clin Invest, 2015 Sep 02; 125(9). PMID: 26325036    Free PMC article.
Highly Cited. Review.
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors.
Maël Heiblig, Mohamed Elhamri, Mauricette Michallet, Xavier Thomas.
World J Stem Cells, 2015 Sep 04; 7(7). PMID: 26328018    Free PMC article.
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
David L Porter, Wei-Ting Hwang, +15 authors, Carl H June.
Sci Transl Med, 2015 Sep 04; 7(303). PMID: 26333935    Free PMC article.
Highly Cited.
Smart CARs engineered for cancer immunotherapy.
Saul J Priceman, Stephen J Forman, Christine E Brown.
Curr Opin Oncol, 2015 Sep 10; 27(6). PMID: 26352543    Free PMC article.
Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
Keith Schutsky, D Gang Song, +5 authors, Daniel J Powell.
Oncotarget, 2015 Sep 12; 6(30). PMID: 26359629    Free PMC article.
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.
D Sommermeyer, M Hudecek, +4 authors, S R Riddell.
Leukemia, 2015 Sep 16; 30(2). PMID: 26369987    Free PMC article.
Highly Cited.
Lymphoma Immunotherapy: Current Status.
Roberta Zappasodi, Filippo de Braud, Massimo Di Nicola.
Front Immunol, 2015 Sep 22; 6. PMID: 26388871    Free PMC article.
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.
Chia-Yung Wu, Kole T Roybal, +2 authors, Wendell A Lim.
Science, 2015 Sep 26; 350(6258). PMID: 26405231    Free PMC article.
Highly Cited.
Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.
Blythe D Sather, Guillermo S Romano Ibarra, +12 authors, David J Rawlings.
Sci Transl Med, 2015 Oct 02; 7(307). PMID: 26424571    Free PMC article.
Highly Cited.
CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).
Sarah K Tasian, Rebecca A Gardner.
Ther Adv Hematol, 2015 Oct 02; 6(5). PMID: 26425336    Free PMC article.
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.
Zeguo Zhao, Maud Condomines, +5 authors, Michel Sadelain.
Cancer Cell, 2015 Oct 16; 28(4). PMID: 26461090    Free PMC article.
Highly Cited.
Novel immunotherapies in lymphoid malignancies.
Connie Lee Batlevi, Eri Matsuki, Renier J Brentjens, Anas Younes.
Nat Rev Clin Oncol, 2015 Nov 04; 13(1). PMID: 26525683    Free PMC article.
Highly Cited. Review.
CAR T-cell immunotherapy: The path from the by-road to the freeway?
Lynsey M Whilding, John Maher.
Mol Oncol, 2015 Nov 14; 9(10). PMID: 26563646    Free PMC article.
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment.
Luo Gu, David J Mooney.
Nat Rev Cancer, 2015 Dec 24; 16(1). PMID: 26694936    Free PMC article.
Highly Cited. Review.
Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.
Hannah Karlsson, Emma Svensson, +5 authors, Angelica Loskog.
PLoS One, 2015 Dec 25; 10(12). PMID: 26700307    Free PMC article.
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
Daniel T Harris, David M Kranz.
Trends Pharmacol Sci, 2015 Dec 26; 37(3). PMID: 26705086    Free PMC article.
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
David T Rodgers, Magdalena Mazagova, +15 authors, Travis S Young.
Proc Natl Acad Sci U S A, 2016 Jan 14; 113(4). PMID: 26759369    Free PMC article.
Highly Cited.
Chimeric antigen receptor-redirected T cells return to the bench.
Claudia Geldres, Barbara Savoldo, Gianpietro Dotti.
Semin Immunol, 2016 Jan 23; 28(1). PMID: 26797495    Free PMC article.
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Joseph A Fraietta, Kyle A Beckwith, +24 authors, Marcela V Maus.
Blood, 2016 Jan 28; 127(9). PMID: 26813675    Free PMC article.
Highly Cited.
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.
Hanren Dai, Yao Wang, Xuechun Lu, Weidong Han.
J Natl Cancer Inst, 2016 Jan 29; 108(7). PMID: 26819347    Free PMC article.
Highly Cited. Review.
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.
Kinga Majchrzak, Michelle H Nelson, +5 authors, Chrystal M Paulos.
Cancer Immunol Immunother, 2016 Jan 31; 65(3). PMID: 26825102    Free PMC article.
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).
Ciara L Freeman, John G Gribben.
Curr Hematol Malig Rep, 2016 Feb 10; 11(1). PMID: 26857283    Free PMC article.
High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.
R C Lynn, Y Feng, +4 authors, D J Powell.
Leukemia, 2016 Feb 24; 30(6). PMID: 26898190    Free PMC article.
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.
Nathan Singh, Irina Kulikovskaya, +7 authors, Stephan A Grupp.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942053    Free PMC article.
Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
Mark O'Hara, Caitlin Stashwick, Andrew R Haas, Janos L Tanyi.
Immunotherapy, 2016 Mar 15; 8(4). PMID: 26973126    Free PMC article.
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.
Yelei Guo, Yao Wang, Weidong Han.
J Immunol Res, 2016 Mar 22; 2016. PMID: 26998495    Free PMC article.
Chimeric antigen receptor-modified T cells strike back.
Matthew J Frigault, Marcela V Maus.
Int Immunol, 2016 Mar 30; 28(7). PMID: 27021308    Free PMC article.
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.
Marcela V Maus, Carl H June.
Clin Cancer Res, 2016 Apr 17; 22(8). PMID: 27084741    Free PMC article.
Highly Cited. Review.
CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Nathan Singh, Noelle V Frey, Stephan A Grupp, Shannon L Maude.
Curr Treat Options Oncol, 2016 Apr 22; 17(6). PMID: 27098534
Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.
Ajoy Dias, Saad J Kenderian, Gustavo F Westin, Mark R Litzow.
Curr Hematol Malig Rep, 2016 Apr 22; 11(4). PMID: 27101015
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.
Agnes Shuk-Yee Lo, Chen Xu, Akikazu Murakami, Wayne A Marasco.
Mol Ther Oncolytics, 2014 Jan 01; 1. PMID: 27119093    Free PMC article.
Strategies to genetically engineer T cells for cancer immunotherapy.
Timothy T Spear, Kaoru Nagato, Michael I Nishimura.
Cancer Immunol Immunother, 2016 May 04; 65(6). PMID: 27138532    Free PMC article.
Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer.
Yu Cao, David T Rodgers, +17 authors, Travis S Young.
Angew Chem Int Ed Engl, 2016 May 05; 55(26). PMID: 27145250    Free PMC article.
How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.
Albert T Gacerez, Benjamine Arellano, Charles L Sentman.
J Cell Physiol, 2016 May 11; 231(12). PMID: 27163336    Free PMC article.
Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer.
Chuan Jin, Grammatiki Fotaki, +3 authors, Di Yu.
EMBO Mol Med, 2016 May 18; 8(7). PMID: 27189167    Free PMC article.
Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.
Hiroki Torikai, Laurence Jn Cooper.
Mol Ther, 2016 May 21; 24(7). PMID: 27203439    Free PMC article.
CAR T Cell Therapy: A Game Changer in Cancer Treatment.
Hilde Almåsbak, Tanja Aarvak, Mohan C Vemuri.
J Immunol Res, 2016 Jun 15; 2016. PMID: 27298832    Free PMC article.
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
Avery D Posey, Robert D Schwab, +19 authors, Carl H June.
Immunity, 2016 Jun 23; 44(6). PMID: 27332733    Free PMC article.
Highly Cited.
A Perspective of Immunotherapy for Prostate Cancer.
Ida Silvestri, Susanna Cattarino, +3 authors, Alessandro Sciarra.
Cancers (Basel), 2016 Jul 12; 8(7). PMID: 27399780    Free PMC article.
Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.
M Kazim Panjwani, Jenessa B Smith, +4 authors, Nicola J Mason.
Mol Ther, 2016 Jul 13; 24(9). PMID: 27401141    Free PMC article.
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Jenessa B Smith, Evripidis Lanitis, +5 authors, Daniel J Powell.
Mol Ther, 2016 Jul 22; 24(11). PMID: 27439899    Free PMC article.
Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
De-Gang Song, Qunrui Ye, +3 authors, Daniel J Powell.
J Hematol Oncol, 2016 Jul 22; 9(1). PMID: 27439908    Free PMC article.
Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.
Yun Bai, Shifeng Kan, +5 authors, Hongkui Deng.
Cell Discov, 2015 Jan 01; 1. PMID: 27462436    Free PMC article.
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.
Nadia Mensali, Fan Ying, +9 authors, Johanna Olweus.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467957    Free PMC article.
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.
Marco Ruella, Carl H June.
Curr Hematol Malig Rep, 2016 Aug 01; 11(5). PMID: 27475429
Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Wenpeng Li, Linjie Guo, +8 authors, Andras Heczey.
Hum Gene Ther, 2016 Aug 18; 28(5). PMID: 27530312    Free PMC article.
Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Radhika Thokala, Simon Olivares, +9 authors, Laurence J N Cooper.
PLoS One, 2016 Aug 23; 11(8). PMID: 27548616    Free PMC article.
Engineered T cells: the promise and challenges of cancer immunotherapy.
Andrew D Fesnak, Carl H June, Bruce L Levine.
Nat Rev Cancer, 2016 Aug 24; 16(9). PMID: 27550819    Free PMC article.
Highly Cited. Review.
Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L+ T Cells for Manufacturing of Gene Therapy Medicinal Products.
Christoph Priesner, Krasimira Aleksandrova, +10 authors, Ulrike Koehl.
Hum Gene Ther, 2016 Aug 27; 27(10). PMID: 27562135    Free PMC article.
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
Marco Ruella, David M Barrett, +18 authors, Saar Gill.
J Clin Invest, 2016 Aug 30; 126(10). PMID: 27571406    Free PMC article.
Highly Cited.
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.
Saad S Kenderian, David L Porter, Saar Gill.
Biol Blood Marrow Transplant, 2016 Sep 18; 23(2). PMID: 27638367    Free PMC article.
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination.
Anke Redeker, Ramon Arens.
Front Immunol, 2016 Sep 23; 7. PMID: 27656185    Free PMC article.
Recent advances and novel treatment paradigms in acute lymphocytic leukemia.
Nikolaos Papadantonakis, Anjali S Advani.
Ther Adv Hematol, 2016 Oct 04; 7(5). PMID: 27695616    Free PMC article.
Recent advances in T-cell engineering for use in immunotherapy.
Preeti Sharma, David M Kranz.
F1000Res, 2016 Oct 06; 5. PMID: 27703664    Free PMC article.
Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome.
Linan Wang, Ning Ma, +7 authors, Hiroshi Shiku.
Oncoimmunology, 2016 Oct 21; 5(9). PMID: 27757303    Free PMC article.
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies.
Marco Ruella, Marcela V Maus.
Comput Struct Biotechnol J, 2016 Oct 21; 14. PMID: 27761200    Free PMC article.
Highly Cited. Review.
Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
Qiong J Wang, Zhiya Yu, +4 authors, James C Yang.
Clin Cancer Res, 2016 Nov 03; 23(9). PMID: 27803044    Free PMC article.
Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research.
Kanako Inoo, Ryo Inagaki, +4 authors, Naoki Okada.
Mol Ther Oncolytics, 2016 Dec 03; 3. PMID: 27909701    Free PMC article.
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.
Noelle V Frey, David L Porter.
Hematology Am Soc Hematol Educ Program, 2016 Dec 04; 2016(1). PMID: 27913530    Free PMC article.
Driving gene-engineered T cell immunotherapy of cancer.
Laura A Johnson, Carl H June.
Cell Res, 2016 Dec 28; 27(1). PMID: 28025979    Free PMC article.
Highly Cited. Review.
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
Elise A Chong, J Joseph Melenhorst, +5 authors, Stephen J Schuster.
Blood, 2016 Dec 30; 129(8). PMID: 28031179    Free PMC article.
Highly Cited.
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Xiao-Yi Tang, Yao Sun, +5 authors, Hu Chen.
BMJ Open, 2017 Jan 01; 6(12). PMID: 28039295    Free PMC article.
T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients.
Yarne Klaver, Sabine C L van Steenbergen, +2 authors, Cor H J Lamers.
Front Immunol, 2017 Jan 14; 7. PMID: 28082983    Free PMC article.
Improving T Cell Expansion with a Soft Touch.
Lester H Lambert, Geraldine K E Goebrecht, +6 authors, Lance C Kam.
Nano Lett, 2017 Jan 27; 17(2). PMID: 28122453    Free PMC article.
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.
Malika Hale, Taylor Mesojednik, +6 authors, Thor A Wagner.
Mol Ther, 2017 Feb 02; 25(3). PMID: 28143740    Free PMC article.
Highly Cited.
Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.
Julien Fleurence, Sophie Fougeray, +5 authors, Stéphane Birklé.
J Immunol Res, 2017 Feb 06; 2017. PMID: 28154831    Free PMC article.
Applications of Immunogenomics to Cancer.
X Shirley Liu, Elaine R Mardis.
Cell, 2017 Feb 12; 168(4). PMID: 28187283    Free PMC article.
Highly Cited. Review.
CARs in the Lead Against Multiple Myeloma.
Maria Ormhøj, Felipe Bedoya, Matthew J Frigault, Marcela V Maus.
Curr Hematol Malig Rep, 2017 Feb 25; 12(2). PMID: 28233151    Free PMC article.
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
Le Qin, Yunxin Lai, +16 authors, Peng Li.
J Hematol Oncol, 2017 Mar 16; 10(1). PMID: 28288656    Free PMC article.
Setting the target for pemphigus vulgaris therapy.
Christoph T Ellebrecht, Aimee S Payne.
JCI Insight, 2017 Mar 16; 2(5). PMID: 28289723    Free PMC article.
Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Shinichi Makita, Kiyoshi Yoshimura, Kensei Tobinai.
Cancer Sci, 2017 Mar 17; 108(6). PMID: 28301076    Free PMC article.
Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells.
Malika Hale, Baeckseung Lee, +9 authors, David J Rawlings.
Mol Ther Methods Clin Dev, 2017 Mar 28; 4. PMID: 28345004    Free PMC article.
Chimeric antigen receptor engineered stem cells: a novel HIV therapy.
Anjie Zhen, Mayra A Carrillo, Scott G Kitchen.
Immunotherapy, 2017 Mar 31; 9(5). PMID: 28357916    Free PMC article.
The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.
Richard P Junghans.
Cancer Gene Ther, 2017 Apr 11; 24(3). PMID: 28392558
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.
ZeNan L Chang, Yvonne Y Chen.
Trends Mol Med, 2017 Apr 19; 23(5). PMID: 28416139    Free PMC article.
CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.
Jeannette Fischer, Claudia Paret, +12 authors, Jörg Faber.
J Immunother, 2017 Apr 26; 40(5). PMID: 28441264    Free PMC article.
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.
Kole T Roybal, Wendell A Lim.
Annu Rev Immunol, 2017 Apr 28; 35. PMID: 28446063    Free PMC article.
Engineering Chimeric Antigen Receptors.
S V Kulemzin, V V Kuznetsova, +2 authors, A A Gorchakov.
Acta Naturae, 2017 May 04; 9(1). PMID: 28461969    Free PMC article.
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
Esther Drent, Maria Themeli, +9 authors, Tuna Mutis.
Mol Ther, 2017 May 17; 25(8). PMID: 28506593    Free PMC article.
Highly Cited.
Genetic Modification of T Cells.
Richard A Morgan, Benjamin Boyerinas.
Biomedicines, 2017 May 26; 4(2). PMID: 28536376    Free PMC article.
Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.
Michael Schmueck-Henneresse, Bilal Omer, +9 authors, Cliona M Rooney.
J Immunol, 2017 May 28; 199(1). PMID: 28550199    Free PMC article.
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.
Congcong Zhang, Pranav Oberoi, +4 authors, Winfried S Wels.
Front Immunol, 2017 Jun 03; 8. PMID: 28572802    Free PMC article.
Highly Cited.
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.
Marco Ruella, Michael Klichinsky, +7 authors, Saar Gill.
Cancer Discov, 2017 Jun 04; 7(10). PMID: 28576927    Free PMC article.
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.
Olaf Oberschmidt, Stephan Kloess, Ulrike Koehl.
Front Immunol, 2017 Jun 27; 8. PMID: 28649246    Free PMC article.
In Vivo Murine-Matured Human CD3+ Cells as a Preclinical Model for T Cell-Based Immunotherapies.
Kevin G Haworth, Christina Ironside, +3 authors, Hans-Peter Kiem.
Mol Ther Methods Clin Dev, 2017 Jun 27; 6. PMID: 28649577    Free PMC article.
Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Marlise R Luskin, Daniel J DeAngelo.
Curr Hematol Malig Rep, 2017 Jun 29; 12(4). PMID: 28656487
5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.
Xueyang Guo, Hang Zheng, +3 authors, Kaitai Yao.
Sci Rep, 2017 Jul 09; 7(1). PMID: 28687750    Free PMC article.
Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.
Tam Nm Dinh, Alexandra S Onea, Ali R Jazirehi.
Am J Clin Exp Immunol, 2017 Aug 15; 6(3). PMID: 28804691    Free PMC article.
CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells.
Mireya Paulina Velasquez, Arpad Szoor, +5 authors, Stephen Gottschalk.
Cancer Immunol Res, 2017 Aug 20; 5(10). PMID: 28821531    Free PMC article.
Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells.
Y Lai, J Weng, +14 authors, P Li.
Leukemia, 2017 Aug 26; 32(3). PMID: 28841215
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
Mingxue Fan, Minghao Li, +5 authors, Lei Yu.
J Hematol Oncol, 2017 Aug 31; 10(1). PMID: 28851445    Free PMC article.
Highly Cited. Review.
Chimeric antigen receptor T-cell therapies for lymphoma.
Jennifer N Brudno, James N Kochenderfer.
Nat Rev Clin Oncol, 2017 Sep 01; 15(1). PMID: 28857075
Highly Cited. Review.
Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs.
Chao Wang, Wujin Sun, +2 authors, Zhen Gu.
Theranostics, 2017 Sep 16; 7(14). PMID: 28912891    Free PMC article.
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Karen Thudium Mueller, Shannon L Maude, +11 authors, Simon F Lacey.
Blood, 2017 Sep 25; 130(21). PMID: 28935694    Free PMC article.
Highly Cited.
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.
Biliang Hu, Jiangtao Ren, +5 authors, Carl H June.
Cell Rep, 2017 Sep 28; 20(13). PMID: 28954221    Free PMC article.
Highly Cited.
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.
Diogo Gomes-Silva, Malini Mukherjee, +8 authors, Maksim Mamonkin.
Cell Rep, 2017 Oct 06; 21(1). PMID: 28978471    Free PMC article.
Highly Cited.
Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor.
Rachel S Leibman, Max W Richardson, +14 authors, James L Riley.
PLoS Pathog, 2017 Oct 13; 13(10). PMID: 29023549    Free PMC article.
CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
Irene M Min, Enda Shevlin, +13 authors, Moonsoo M Jin.
Clin Cancer Res, 2017 Oct 14; 23(24). PMID: 29025766    Free PMC article.
Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.
Michael Merker, Verena Pfirrmann, +5 authors, Eva Rettinger.
Oncotarget, 2017 Oct 17; 8(39). PMID: 29029499    Free PMC article.
Clinical trials of CAR-T cells in China.
Bingshan Liu, Yongping Song, Delong Liu.
J Hematol Oncol, 2017 Oct 24; 10(1). PMID: 29058636    Free PMC article.
Highly Cited.
Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Eduardo Laborda, Magdalena Mazagova, +8 authors, Travis S Young.
Int J Mol Sci, 2017 Oct 28; 18(11). PMID: 29077054    Free PMC article.
Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response.
Qiong Xue, Emily Bettini, +11 authors, Jing Zhou.
J Immunother Cancer, 2017 Nov 22; 5(1). PMID: 29157295    Free PMC article.
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.
Sang Yun Lee, Philip Olsen, +9 authors, Brian G Till.
J Immunother, 2017 Nov 28; 41(1). PMID: 29176334    Free PMC article.
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
Tiara T Byrd, Kristen Fousek, +22 authors, Nabil Ahmed.
Cancer Res, 2017 Dec 01; 78(2). PMID: 29183891    Free PMC article.
Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.
Katherine T Marcucci, Julie K Jadlowsky, +10 authors, Carl H June.
Mol Ther, 2017 Dec 06; 26(1). PMID: 29203150    Free PMC article.
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
Christopher A Klebanoff, Joseph G Crompton, +16 authors, Nicholas P Restifo.
JCI Insight, 2017 Dec 08; 2(23). PMID: 29212954    Free PMC article.
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Stephen J Schuster, Jakub Svoboda, +13 authors, Carl H June.
N Engl J Med, 2017 Dec 12; 377(26). PMID: 29226764    Free PMC article.
Highly Cited.
Emerging trends in the immunotherapy of pancreatic cancer.
Kasturi Banerjee, Sushil Kumar, +10 authors, Maneesh Jain.
Cancer Lett, 2017 Dec 16; 417. PMID: 29242097    Free PMC article.
Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.
Saul J Priceman, Ethan A Gerdts, +15 authors, Stephen J Forman.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308300    Free PMC article.
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
Shivani Srivastava, Stanley R Riddell.
J Immunol, 2018 Jan 10; 200(2). PMID: 29311388    Free PMC article.
Highly Cited. Review.
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Sonia Guedan, Avery D Posey, +14 authors, Carl H June.
JCI Insight, 2018 Jan 13; 3(1). PMID: 29321369    Free PMC article.
Highly Cited.
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells.
Kevin G Pinz, Elizabeth Yakaboski, +11 authors, Yupo Ma.
Oncotarget, 2018 Jan 20; 8(68). PMID: 29348865    Free PMC article.
Optimized DNA electroporation for primary human T cell engineering.
Zhang Zhang, Shunfang Qiu, Xiaopeng Zhang, Wei Chen.
BMC Biotechnol, 2018 Jan 31; 18(1). PMID: 29378552    Free PMC article.
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, +32 authors, Stephan A Grupp.
N Engl J Med, 2018 Feb 01; 378(5). PMID: 29385370    Free PMC article.
Highly Cited.
Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression.
Chungyong Han, Su-Jung Sim, +11 authors, Byoung S Kwon.
Nat Commun, 2018 Feb 03; 9(1). PMID: 29391449    Free PMC article.
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Yuki Kagoya, Shinya Tanaka, +6 authors, Naoto Hirano.
Nat Med, 2018 Feb 06; 24(3). PMID: 29400710    Free PMC article.
Highly Cited.
CAR-T cells: the long and winding road to solid tumors.
Maria Michela D'Aloia, Ilaria Grazia Zizzari, +2 authors, Maurizio Alimandi.
Cell Death Dis, 2018 Feb 17; 9(3). PMID: 29449531    Free PMC article.
Highly Cited. Review.
CD137+CD154- Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from In Vitro Expansion Cultures.
Anna Nowak, Dominik Lock, +9 authors, Alexander Scheffold.
Front Immunol, 2018 Feb 23; 9. PMID: 29467769    Free PMC article.
T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.
Michaela E Sharpe.
Toxicol Pathol, 2018 Feb 24; 46(2). PMID: 29471776    Free PMC article.
In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
Zhi Cheng, Runhong Wei, +15 authors, Pin Wang.
Mol Ther, 2018 Mar 06; 26(4). PMID: 29503204    Free PMC article.
T-bet promotes potent antitumor activity of CD4+ CAR T cells.
Albert T Gacerez, Charles L Sentman.
Cancer Gene Ther, 2018 Mar 09; 25(5-6). PMID: 29515240    Free PMC article.
The Pharmacology of T Cell Therapies.
Michael C Milone, Vijay G Bhoj.
Mol Ther Methods Clin Dev, 2018 Mar 20; 8. PMID: 29552577    Free PMC article.
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma.
Zhongzhen Yi, Brooke L Prinzing, +2 authors, Giedre Krenciute.
Mol Ther Methods Clin Dev, 2018 Mar 20; 9. PMID: 29552579    Free PMC article.
The development of CAR design for tumor CAR-T cell therapy.
Dandan Xu, Guoliang Jin, +5 authors, Junnian Zheng.
Oncotarget, 2018 Mar 24; 9(17). PMID: 29568411    Free PMC article.
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Kevin M Friedman, Tracy E Garrett, +5 authors, Richard A Morgan.
Hum Gene Ther, 2018 Apr 12; 29(5). PMID: 29641319    Free PMC article.
Highly Cited.
Clinical use of lentiviral vectors.
Michael C Milone, Una O'Doherty.
Leukemia, 2018 Apr 15; 32(7). PMID: 29654266    Free PMC article.
Highly Cited. Review.
False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy.
Theodore W Laetsch, Shannon L Maude, +7 authors, Stephan A Grupp.
Blood, 2018 Apr 20; 131(23). PMID: 29669777    Free PMC article.
The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations.
Roddy S O'Connor, Lili Guo, +10 authors, Michael C Milone.
Sci Rep, 2018 Apr 21; 8(1). PMID: 29674640    Free PMC article.
An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.
Marcela V Maus, Jason Plotkin, +6 authors, Michel Sadelain.
Mol Ther Oncolytics, 2017 Jan 11; 3. PMID: 29675462    Free PMC article.
Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium.
Andrew R Medvec, Christopher Ecker, +4 authors, James L Riley.
Mol Ther Methods Clin Dev, 2018 Apr 25; 8. PMID: 29687031    Free PMC article.
Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.
Anandani Nellan, Christopher Rota, +6 authors, Daniel W Lee.
J Immunother Cancer, 2018 May 02; 6(1). PMID: 29712574    Free PMC article.
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Joseph A Fraietta, Simon F Lacey, +34 authors, J Joseph Melenhorst.
Nat Med, 2018 May 02; 24(5). PMID: 29713085    Free PMC article.
Highly Cited.
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.
Yanyu Pang, Xiaoyang Hou, +2 authors, Guan Jiang.
Mol Cancer, 2018 May 18; 17(1). PMID: 29769134    Free PMC article.
Are ovarian cancer stem cells the target for innovative immunotherapy?
Liang Wang, Tianmin Xu, Manhua Cui.
Onco Targets Ther, 2018 May 22; 11. PMID: 29780254    Free PMC article.
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.
Christopher C Kloss, Jihyun Lee, +7 authors, Carl H June.
Mol Ther, 2018 May 29; 26(7). PMID: 29807781    Free PMC article.
Highly Cited.
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Miriam Y Kim, Kyung-Rok Yu, +22 authors, Saar Gill.
Cell, 2018 Jun 02; 173(6). PMID: 29856956    Free PMC article.
Highly Cited.
PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
David C Bishop, Ning Xu, +4 authors, Kenneth P Micklethwaite.
Mol Ther, 2018 Jun 05; 26(8). PMID: 29861327    Free PMC article.
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.
Concetta Quintarelli, Domenico Orlando, +14 authors, Ignazio Caruana.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872565    Free PMC article.
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.
De-Xiu Bu, Reshma Singh, +19 authors, Michael C Milone.
Oncotarget, 2018 Jun 15; 9(40). PMID: 29899820    Free PMC article.
Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.
Antoni Xavier Torres-Collado, Ali R Jazirehi.
Cancers (Basel), 2018 Jun 16; 10(6). PMID: 29904021    Free PMC article.
Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation.
Scott S Graves, Maura H Parker, Rainer Storb.
ILAR J, 2018 Jul 17; 59(3). PMID: 30010833    Free PMC article.
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges.
Zijun Zhao, Yu Chen, +2 authors, Minhao Wu.
Acta Pharm Sin B, 2018 Aug 16; 8(4). PMID: 30109179    Free PMC article.
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Katherine C Pehlivan, Brynn B Duncan, Daniel W Lee.
Curr Hematol Malig Rep, 2018 Aug 19; 13(5). PMID: 30120708
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
Hannah M Knochelmann, Aubrey S Smith, +3 authors, Chrystal M Paulos.
Front Immunol, 2018 Aug 25; 9. PMID: 30140266    Free PMC article.
Highly Cited. Review.
Strategies to Address Chimeric Antigen Receptor Tonic Signaling.
Adam Ajina, John Maher.
Mol Cancer Ther, 2018 Sep 06; 17(9). PMID: 30181329    Free PMC article.
Combining immunotherapy with radiation therapy in thoracic oncology.
Shahed N Badiyan, Michael C Roach, +7 authors, Charles B Simone.
J Thorac Dis, 2018 Sep 13; 10(Suppl 21). PMID: 30206494    Free PMC article.
Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
Kathleen Nagle, Barbara Tafuto, Lisa Palladino Kim, J Scott Parrott.
Med Oncol, 2018 Sep 13; 35(11). PMID: 30206753
Systematic Review.
4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Gongbo Li, Justin C Boucher, +8 authors, Marco L Davila.
JCI Insight, 2018 Sep 21; 3(18). PMID: 30232281    Free PMC article.
The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL.
Matthew H Forsberg, Amritava Das, Krishanu Saha, Christian M Capitini.
Ther Clin Risk Manag, 2018 Sep 21; 14. PMID: 30233192    Free PMC article.
Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside.
Luis G Rodriguez-Cartagena, Bradley S Bowles, +3 authors, Alexandra J Greenberg-Worisek.
Clin Transl Sci, 2018 Sep 23; 11(6). PMID: 30242965    Free PMC article.
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.
Jun Zhang, L Jeffrey Medeiros, Ken H Young.
Front Oncol, 2018 Sep 27; 8. PMID: 30250823    Free PMC article.
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
Hui Zhou, Yuling Luo, +5 authors, Xuelei Ma.
BMC Cancer, 2018 Sep 28; 18(1). PMID: 30257649    Free PMC article.
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory.
Sophie Viaud, Jennifer S Y Ma, +10 authors, Travis S Young.
Proc Natl Acad Sci U S A, 2018 Oct 31; 115(46). PMID: 30373813    Free PMC article.
CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors.
Anna C Filley, Mario Henriquez, Mahua Dey.
Front Oncol, 2018 Nov 06; 8. PMID: 30386740    Free PMC article.
Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy.
Victoria G Kravets, Yi Zhang, Hongxing Sun.
J Immunol Res Ther, 2017 Jun 01; 2(1). PMID: 30443604    Free PMC article.
A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release.
Yiyang Xu, Zhiyuan Yang, +11 authors, Cheng Liu.
Cell Discov, 2018 Nov 28; 4. PMID: 30479831    Free PMC article.
Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.
John P Murad, Anna K Kozlowska, +8 authors, Saul J Priceman.
Front Immunol, 2018 Dec 05; 9. PMID: 30510550    Free PMC article.
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.
Stephanie Vairy, Julia Lopes Garcia, Pierre Teira, Henrique Bittencourt.
Drug Des Devel Ther, 2018 Dec 07; 12. PMID: 30518999    Free PMC article.
Immunotherapy for pediatric brain tumors: past and present.
Jessica B Foster, Peter J Madsen, +6 authors, Angela J Waanders.
Neuro Oncol, 2019 Sep 11; 21(10). PMID: 31504801    Free PMC article.
Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.
William R Strohl, Michael Naso.
Antibodies (Basel), 2019 Sep 24; 8(3). PMID: 31544847    Free PMC article.
CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.
Gloria B Kim, Kristen Hege, James L Riley.
Front Immunol, 2019 Oct 16; 10. PMID: 31611880    Free PMC article.
Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer.
Yufeng Shang, Fuling Zhou.
Front Oncol, 2019 Oct 17; 9. PMID: 31616632    Free PMC article.
CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives.
Qun Zeng, Yubin Zhou, Herbert Schwarz.
Front Immunol, 2019 Oct 22; 10. PMID: 31632390    Free PMC article.
Genetically engineered T cells for cancer immunotherapy.
Dan Li, Xue Li, +8 authors, Wei Wang.
Signal Transduct Target Ther, 2019 Oct 23; 4. PMID: 31637014    Free PMC article.
Preclinical Proof-of-Concept, Analytical Development, and Commercial Scale Production of Lentiviral Vector in Adherent Cells.
Hanna M Leinonen, Eevi M Lipponen, +10 authors, Hanna P Lesch.
Mol Ther Methods Clin Dev, 2019 Oct 28; 15. PMID: 31649956    Free PMC article.
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Andrea Schmidts, Maria Ormhøj, +17 authors, Marcela V Maus.
Blood Adv, 2019 Nov 08; 3(21). PMID: 31698455    Free PMC article.
Immune-Based Therapies in Acute Leukemia.
Matthew T Witkowski, Audrey Lasry, William L Carroll, Iannis Aifantis.
Trends Cancer, 2019 Nov 11; 5(10). PMID: 31706508    Free PMC article.
CAR T-cell therapy: is it prime time in myeloma?
Surbhi Sidana, Nina Shah.
Blood Adv, 2019 Nov 13; 3(21). PMID: 31714964    Free PMC article.
Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe.
Jochen Buechner, Marie José Kersten, +2 authors, Ulrich Jäger.
Hemasphere, 2018 Feb 02; 2(1). PMID: 31723747    Free PMC article.
Current Progress in CAR-T Cell Therapy for Solid Tumors.
Shuo Ma, Xinchun Li, +5 authors, Qijun Qian.
Int J Biol Sci, 2019 Nov 23; 15(12). PMID: 31754328    Free PMC article.
CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm.
LaQuisa Hill, Premal Lulla, Helen E Heslop.
Adv Cell Gene Ther, 2019 Nov 30; 2(3). PMID: 31777773    Free PMC article.
CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases.
Michelle Seif, Hermann Einsele, Jürgen Löffler.
Front Immunol, 2019 Dec 12; 10. PMID: 31824500    Free PMC article.
CAR T Cell Therapy for Hematological Malignancies.
Xin Yang, Gao-Xiang Wang, Jian-Feng Zhou.
Curr Med Sci, 2019 Dec 18; 39(6). PMID: 31845217
Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene.
Mark A Sellmyer, Sarah A Richman, +6 authors, Michael D Farwell.
Mol Ther, 2019 Nov 02; 28(1). PMID: 31668558    Free PMC article.
CAR T-cell therapy: is it prime time in myeloma?
Surbhi Sidana, Nina Shah.
Hematology Am Soc Hematol Educ Program, 2019 Dec 07; 2019(1). PMID: 31808895    Free PMC article.
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
Norris Lam, Nathan D Trinklein, +3 authors, James N Kochenderfer.
Nat Commun, 2020 Jan 17; 11(1). PMID: 31941907    Free PMC article.
Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
Hidefumi Hiramatsu, Souichi Adachi, +7 authors, Stephan A Grupp.
Int J Hematol, 2019 Nov 12; 111(2). PMID: 31709501
CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.
Holly L Pacenta, Theodore W Laetsch, Samuel John.
Paediatr Drugs, 2019 Nov 22; 22(1). PMID: 31749131
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials.
Seshu Tyagarajan, Tom Spencer, Jonathan Smith.
Mol Ther Methods Clin Dev, 2020 Jan 29; 16. PMID: 31988978    Free PMC article.
Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy.
Pedro Roda-Navarro, Luis Álvarez-Vallina.
Front Cell Dev Biol, 2020 Jan 31; 7. PMID: 31998721    Free PMC article.
Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Talha Badar, Nirav N Shah.
Curr Treat Options Oncol, 2020 Feb 07; 21(2). PMID: 32025828
Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
Prativa Sahoo, Xin Yang, +11 authors, Russell C Rockne.
J R Soc Interface, 2020 Jan 16; 17(162). PMID: 31937234    Free PMC article.
Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Ryan D Salinas, Joseph S Durgin, Donald M O'Rourke.
CNS Drugs, 2020 Jan 10; 34(2). PMID: 31916100
A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells.
Marco Ruella, David M Barrett, +8 authors, Saar I Gill.
Blood, 2019 Nov 09; 135(7). PMID: 31703119    Free PMC article.
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Peter Braendstrup, Bruce L Levine, Marco Ruella.
Cytotherapy, 2020 Feb 06; 22(2). PMID: 32014447    Free PMC article.
Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases.
Yuehong Chen, Jianhong Sun, +2 authors, Qibing Xie.
J Immunol Res, 2020 Feb 23; 2019. PMID: 32083141    Free PMC article.
[Construction of specific artificial antigen-presenting cells for in vitro activation of CD19 chimeric antigen receptor T cells].
Yao-Jun Peng, Qi-Yan Wu, +2 authors, Hua-Feng Wei.
Nan Fang Yi Ke Da Xue Xue Bao, 2017 May 26; 37(5). PMID: 28539278    Free PMC article.
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Lena Andersch, Josefine Radke, +13 authors, Annette Künkele.
BMC Cancer, 2019 Sep 11; 19(1). PMID: 31500597    Free PMC article.
Mapping and targeting of the leukemic microenvironment.
Matthew T Witkowski, Stavroula Kousteni, Iannis Aifantis.
J Exp Med, 2019 Dec 25; 217(2). PMID: 31873722    Free PMC article.
The making and function of CAR cells.
Maja Zabel, Peter A Tauber, Winfried F Pickl.
Immunol Lett, 2019 Jun 11; 212. PMID: 31181279    Free PMC article.
Addition of the C-terminus of CD6 to a chimeric antigen receptor enhances cytotoxicity and does not compromise expression.
Johannes Breuning, Brian Philip, Marion H Brown.
Immunology, 2018 Oct 10; 156(2). PMID: 30300924    Free PMC article.
CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
Kristen B Long, Regina M Young, +6 authors, Joseph A Fraietta.
Front Immunol, 2018 Dec 19; 9. PMID: 30559740    Free PMC article.
Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
Matthew R Collinson-Pautz, Wei-Chun Chang, +12 authors, Aaron E Foster.
Leukemia, 2019 Mar 01; 33(9). PMID: 30816327    Free PMC article.
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Adam D Cohen, Alfred L Garfall, +19 authors, Michael C Milone.
J Clin Invest, 2019 Mar 22; 129(6). PMID: 30896447    Free PMC article.
Highly Cited.
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.
Stefan Stoiber, Bruno L Cadilha, +3 authors, Sebastian Kobold.
Cells, 2019 May 22; 8(5). PMID: 31108883    Free PMC article.
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Maria-Luisa Schubert, Anita Schmitt, +13 authors, Michael Schmitt.
BMJ Open, 2019 May 22; 9(5). PMID: 31110096    Free PMC article.
CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo.
Xiaojun Tang, Qi Tang, +4 authors, Zhenqing Feng.
Onco Targets Ther, 2019 Dec 07; 12. PMID: 31807014    Free PMC article.
The future of cellular immunotherapy for childhood leukemia.
Challice L Bonifant, Sarah K Tasian.
Curr Opin Pediatr, 2019 Dec 19; 32(1). PMID: 31851053    Free PMC article.
Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production.
Hanna M Leinonen, Saana Lepola, +5 authors, Hanna P Lesch.
Hum Gene Ther, 2020 Feb 23; 31(5-6). PMID: 32075423    Free PMC article.
Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
Leidy D Caraballo Galva, Lun Cai, Yanxia Shao, Yukai He.
J Genet Genomics, 2020 Feb 25; 47(1). PMID: 32089500    Free PMC article.
Advances in Developing CAR T-Cell Therapy for HIV Cure.
Jinxin Qi, Chengchao Ding, Xian Jiang, Yong Gao.
Front Immunol, 2020 Mar 27; 11. PMID: 32210965    Free PMC article.
State of the art in CAR T cell therapy for CD19+ B cell malignancies.
Matthew J Frigault, Marcela V Maus.
J Clin Invest, 2020 Apr 03; 130(4). PMID: 32235098    Free PMC article.
Use of polyvinyl alcohol for chimeric antigen receptor T-cell expansion.
Toshinobu Nishimura, Ian Hsu, +5 authors, Adam C Wilkinson.
Exp Hematol, 2019 Dec 26; 80. PMID: 31874780    Free PMC article.
Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia.
Veronika Mancikova, Helena Peschelova, +8 authors, Michal Smida.
J Immunother Cancer, 2020 Mar 29; 8(1). PMID: 32217767    Free PMC article.
Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.
Leila Jafarzadeh, Elham Masoumi, +2 authors, Jamshid Hadjati.
Front Immunol, 2020 May 12; 11. PMID: 32391013    Free PMC article.
Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma.
Fangming Liu, Weiren Liu, +9 authors, Duojiao Wu.
Oncoimmunology, 2020 May 20; 9(1). PMID: 32426177    Free PMC article.
Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Robert D Carlson, John C Flickinger, Adam E Snook.
Toxins (Basel), 2020 Apr 15; 12(4). PMID: 32283684    Free PMC article.
Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.
Sonia Guedan, Aviv Madar, +6 authors, Avery D Posey.
J Clin Invest, 2020 Feb 19; 130(6). PMID: 32069268    Free PMC article.
Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells.
Thomas Mika, Abdelouahid Maghnouj, +7 authors, Roland Schroers.
Front Mol Biosci, 2020 Jun 06; 7. PMID: 32500079    Free PMC article.
Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
Angela C Boroughs, Rebecca C Larson, +9 authors, Marcela V Maus.
JCI Insight, 2019 Mar 15; 5. PMID: 30869654    Free PMC article.
Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.
Wai-Hang Leung, Joel Gay, +8 authors, Alexander Astrakhan.
JCI Insight, 2019 May 01; 5. PMID: 31039141    Free PMC article.
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies.
Yuru Nie, Weiqing Lu, +6 authors, Yuhua Li.
Biomark Res, 2020 Jun 10; 8. PMID: 32514351    Free PMC article.
Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.
Ling Wu, Qianru Wei, Joanna Brzostek, Nicholas R J Gascoigne.
Cell Mol Immunol, 2020 May 27; 17(6). PMID: 32451454    Free PMC article.
CARs: Beyond T Cells and T Cell-Derived Signaling Domains.
Nico M Sievers, Jan Dörrie, Niels Schaft.
Int J Mol Sci, 2020 May 21; 21(10). PMID: 32429316    Free PMC article.
Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor.
Nicholas G Minutolo, Prannda Sharma, +9 authors, Daniel J Powell.
J Am Chem Soc, 2020 Mar 20; 142(14). PMID: 32191035    Free PMC article.
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.
Margaret M Billingsley, Nathan Singh, +3 authors, Michael J Mitchell.
Nano Lett, 2020 Jan 18; 20(3). PMID: 31951421    Free PMC article.
CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
Aamir Ahmad, Shahab Uddin, Martin Steinhoff.
Int J Mol Sci, 2020 Jun 04; 21(11). PMID: 32486160    Free PMC article.
Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma.
Fangming Liu, Weiren Liu, +13 authors, Duojiao Wu.
J Immunother Cancer, 2020 Jul 03; 8(2). PMID: 32611686    Free PMC article.
HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo.
Colby R Maldini, Kevin Gayout, +5 authors, James L Riley.
Mol Ther, 2020 May 27; 28(7). PMID: 32454027    Free PMC article.
[Advances in immunotherapy of acute myeloid leukemia by using chimeric antigen receptor modified T cells].
Zhongfei Tao, Min Wang, Jianxiang Wang.
Zhonghua Xue Ye Xue Za Zhi, 2016 Mar 26; 37(2). PMID: 27014990    Free PMC article.
[Anti-CD19 chimeric antigen receptor T cells (CART-19) for hemotological malignancies therapy].
Hejin Jia, Weidong Han.
Zhonghua Xue Ye Xue Za Zhi, 2016 Mar 26; 37(2). PMID: 27014991    Free PMC article.
[An experimental study of CD4 targeted chimeric antigen receptor modified T cell with anti-lymphoma activity].
G H Chen, H W Huang, +14 authors, D P Wu.
Zhonghua Xue Ye Xue Za Zhi, 2018 Mar 22; 39(2). PMID: 29562451    Free PMC article.
Promoter choice: Who should drive the CAR in T cells?
Ali Hosseini Rad S M, Aarati Poudel, Grace Min Yi Tan, Alexander D McLellan.
PLoS One, 2020 Jul 25; 15(7). PMID: 32706785    Free PMC article.
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.
Nathan Singh, Yong Gu Lee, +19 authors, Marco Ruella.
Cancer Discov, 2020 Feb 01; 10(4). PMID: 32001516    Free PMC article.
Chimeric Antigen Receptor Therapy.
Carl H June, Michel Sadelain.
N Engl J Med, 2018 Jul 05; 379(1). PMID: 29972754    Free PMC article.
Highly Cited. Review.
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Karen Thudium Mueller, Edward Waldron, +18 authors, Shannon L Maude.
Clin Cancer Res, 2018 Sep 08; 24(24). PMID: 30190371    Free PMC article.
Highly Cited.
Targeting PD-L1 in non-small cell lung cancer using CAR T cells.
Ming Liu, Xu Wang, +8 authors, Yong Li.
Oncogenesis, 2020 Aug 15; 9(8). PMID: 32792499    Free PMC article.
Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion.
Cong He, Ying Zhou, +9 authors, Wenzheng Jiang.
Cancers (Basel), 2020 Jul 24; 12(7). PMID: 32698361    Free PMC article.
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions.
Luis Gerardo Rodríguez-Lobato, Maya Ganzetti, +3 authors, Sophia Danhof.
Front Oncol, 2020 Aug 28; 10. PMID: 32850376    Free PMC article.
A rational mouse model to detect on-target, off-tumor CAR T cell toxicity.
Mauro Castellarin, Caroline Sands, +6 authors, Carl H June.
JCI Insight, 2020 Jun 17; 5(14). PMID: 32544101    Free PMC article.
Inflammatory Cells in Diffuse Large B Cell Lymphoma.
Roberto Tamma, Girolamo Ranieri, +6 authors, Domenico Ribatti.
J Clin Med, 2020 Aug 01; 9(8). PMID: 32731512    Free PMC article.
Lipidomic-Based Advances in Diagnosis and Modulation of Immune Response to Cancer.
Luis Gil-de-Gómez, David Balgoma, Olimpio Montero.
Metabolites, 2020 Aug 23; 10(8). PMID: 32824009    Free PMC article.
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Esther Drent, Renée Poels, +9 authors, Maria Themeli.
Clin Cancer Res, 2019 Apr 14; 25(13). PMID: 30979735    Free PMC article.
Highly Cited.
Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies.
Belén Blanco, Ángel Ramírez-Fernández, Luis Alvarez-Vallina.
Front Immunol, 2020 Sep 10; 11. PMID: 32903593    Free PMC article.
A safe and potent anti-CD19 CAR T cell therapy.
Zhitao Ying, Xue F Huang, +33 authors, Si-Yi Chen.
Nat Med, 2019 Apr 24; 25(6). PMID: 31011207    Free PMC article.
Highly Cited.
Improving CAR T cell therapy by optimizing critical quality attributes.
Opal L Reddy, David F Stroncek, Sandhya R Panch.
Semin Hematol, 2020 Sep 08; 57(2). PMID: 32892841    Free PMC article.
Chimeric antigen receptor modified T-cells for cancer treatment.
Xiao Han, Yao Wang, Wei-Dong Han.
Chronic Dis Transl Med, 2019 Jan 04; 4(4). PMID: 30603741    Free PMC article.
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.
Maria Castella, Anna Boronat, +30 authors, Manel Juan.
Mol Ther Methods Clin Dev, 2019 Jan 10; 12. PMID: 30623002    Free PMC article.
Engineering and Design of Chimeric Antigen Receptors.
Sonia Guedan, Hugo Calderon, Avery D Posey, Marcela V Maus.
Mol Ther Methods Clin Dev, 2019 Jan 23; 12. PMID: 30666307    Free PMC article.
Highly Cited. Review.
Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches.
MyLinh T Duong, Matthew R Collinson-Pautz, +11 authors, J Henri Bayle.
Mol Ther Oncolytics, 2019 Feb 12; 12. PMID: 30740516    Free PMC article.
Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.
Shinichi Makita, Katsuaki Imaizumi, Saiko Kurosawa, Kensei Tobinai.
Drugs Context, 2019 Mar 01; 8. PMID: 30815024    Free PMC article.
Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis.
Emmanuel Kwateng Drokow, Hafiz Abdul Waqas Ahmed, +4 authors, Kai Sun.
Ther Clin Risk Manag, 2019 Jun 14; 15. PMID: 31190844    Free PMC article.
Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma.
Sujun Li, Lei Xue, +10 authors, Xingbing Wang.
Onco Targets Ther, 2019 Aug 03; 12. PMID: 31372000    Free PMC article.
Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells.
Yuan Fang, Yajun Zhang, +5 authors, Qijun Qian.
Mol Ther Methods Clin Dev, 2020 Oct 01; 19. PMID: 32995356    Free PMC article.
Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges.
Sylwia Jasinski, Francis Andrew De Los Reyes, +3 authors, William L Carroll.
Paediatr Drugs, 2020 Aug 30; 22(5). PMID: 32860590    Free PMC article.
T-cell adoptive immunotherapy for acute lymphoblastic leukemia.
Terry J Fry, Crystal L Mackall.
Hematology Am Soc Hematol Educ Program, 2013 Dec 10; 2013. PMID: 24319203    Free PMC article.
Podoplanin as an Attractive Target of CAR T Cell Therapy.
Masazumi Waseda, Shin Kaneko.
Cells, 2020 Aug 30; 9(9). PMID: 32858947    Free PMC article.
Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data.
Concetta Rafaniello, Carmen Ferrajolo, +6 authors, Annalisa Capuano.
Pharmaceuticals (Basel), 2020 Sep 25; 13(9). PMID: 32967272    Free PMC article.
Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma.
Robert J Cronk, Joanna Zurko, Nirav N Shah.
Cancers (Basel), 2020 Sep 10; 12(9). PMID: 32899464    Free PMC article.
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview.
Niels Schaft.
Cancers (Basel), 2020 Sep 13; 12(9). PMID: 32916883    Free PMC article.
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.
Kevin R Parker, Denis Migliorini, +18 authors, Ansuman T Satpathy.
Cell, 2020 Sep 23; 183(1). PMID: 32961131    Free PMC article.
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Marcelo C Pasquini, Zhen-Huan Hu, +28 authors, Stephan Grupp.
Blood Adv, 2020 Nov 05; 4(21). PMID: 33147337    Free PMC article.
Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers.
Manuel Gotti, Irene Defrancesco, +5 authors, Vincenzo Iaconianni.
Front Immunol, 2020 Nov 17; 11. PMID: 33193333    Free PMC article.
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
Andrew H Ko, Alexander C Jordan, +13 authors, Gregory L Beatty.
Mol Ther, 2020 Jul 31; 28(11). PMID: 32730744    Free PMC article.
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas.
Caron A Jacobson, Marcela V Maus.
Blood Adv, 2020 Nov 25; 4(22). PMID: 33232481    Free PMC article.
Adoptive cell therapy: genetic modification to redirect effector cell specificity.
Richard A Morgan, Mark E Dudley, Steven A Rosenberg.
Cancer J, 2010 Aug 10; 16(4). PMID: 20693844    Free PMC article.
At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
Anthony F O Daniyan, Renier J Brentjens.
J Leukoc Biol, 2016 Oct 30; 100(6). PMID: 27789538    Free PMC article.
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Anna Wing, Carlos Alberto Fajardo, +6 authors, Sonia Guedan.
Cancer Immunol Res, 2018 Mar 29; 6(5). PMID: 29588319    Free PMC article.
Highly Cited.
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.
Marco Ruella, Jun Xu, +23 authors, J Joseph Melenhorst.
Nat Med, 2018 Oct 03; 24(10). PMID: 30275568    Free PMC article.
Highly Cited.
Adoptive cellular therapies: the current landscape.
Maartje W Rohaan, Sofie Wilgenhof, John B A G Haanen.
Virchows Arch, 2018 Nov 25; 474(4). PMID: 30470934    Free PMC article.
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Tiantian Ma, Jing Shi, Huasheng Liu.
Ann Hematol, 2019 Jan 30; 98(4). PMID: 30693373    Free PMC article.
Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy.
Chunmei Yang, Wen Lei, +4 authors, Wenbin Qian.
Onco Targets Ther, 2020 Dec 04; 13. PMID: 33268994    Free PMC article.
4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells.
Qiang Dai, Ping Han, +6 authors, Xuanming Yang.
Front Immunol, 2020 Dec 08; 11. PMID: 33281809    Free PMC article.
Cell and tissue engineering in lymph nodes for cancer immunotherapy.
Alexander J Najibi, David J Mooney.
Adv Drug Deliv Rev, 2020 Aug 05; 161-162. PMID: 32750376    Free PMC article.
Systematic Review.
Adoptive T cell therapy: Boosting the immune system to fight cancer.
Ernesto Leon, Raghuveer Ranganathan, Barbara Savoldo.
Semin Immunol, 2020 Dec 03; 49. PMID: 33262066    Free PMC article.
Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress.
Yixi Zhang, Pan Li, +2 authors, Xun Zeng.
Front Immunol, 2020 Dec 29; 11. PMID: 33362790    Free PMC article.
Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma.
Lorena Perez-Amill, Guillermo Suñe, +10 authors, Beatriz Martín-Antonio.
Haematologica, 2020 Jan 11; 106(1). PMID: 31919085    Free PMC article.
Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
Scott R Goldsmith, Armin Ghobadi, John F DiPersio.
Front Oncol, 2021 Jan 09; 10. PMID: 33415078    Free PMC article.
Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy.
Kai Wang, Yu Zhao, +8 authors, Zhiguo Chen.
Front Immunol, 2021 Jan 12; 11. PMID: 33424835    Free PMC article.
Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
Emiliano Roselli, Rawan Faramand, Marco L Davila.
J Clin Invest, 2021 Jan 20; 131(2). PMID: 33463538    Free PMC article.
Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.
Babak Moghimi, Sakunthala Muthugounder, +7 authors, Shahab Asgharzadeh.
Nat Commun, 2021 Jan 23; 12(1). PMID: 33479234    Free PMC article.
CAR T-cell product performance in haematological malignancies before and after marketing authorisation.
Magdi Elsallab, Bruce L Levine, Alan S Wayne, Mohamed Abou-El-Enein.
Lancet Oncol, 2020 Feb 03; 21(2). PMID: 32007196    Free PMC article.
CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
Justin C Boucher, Gongbo Li, +12 authors, Marco L Davila.
Cancer Immunol Res, 2020 Nov 15; 9(1). PMID: 33188139    Free PMC article.
Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.
Ariel Isser, Natalie K Livingston, Jonathan P Schneck.
Biomaterials, 2020 Dec 19; 268. PMID: 33338931    Free PMC article.
Genome editing of immune cells using CRISPR/Cas9.
Segi Kim, Cedric Hupperetz, Seongjoon Lim, Chan Hyuk Kim.
BMB Rep, 2020 Dec 11; 54(1). PMID: 33298251    Free PMC article.
CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy.
Alba Rodriguez-Garcia, Rachel C Lynn, +8 authors, Daniel J Powell.
Nat Commun, 2021 Feb 11; 12(1). PMID: 33563975    Free PMC article.
Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Christina Amatya, Melissa A Pegues, +6 authors, James N Kochenderfer.
Mol Ther, 2020 Nov 02; 29(2). PMID: 33129371    Free PMC article.
4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling.
Benjamin I Philipson, Roddy S O'Connor, +3 authors, Michael C Milone.
Sci Signal, 2020 Apr 03; 13(625). PMID: 32234960    Free PMC article.
Metabolism of immune cells in cancer.
Robert D Leone, Jonathan D Powell.
Nat Rev Cancer, 2020 Jul 08; 20(9). PMID: 32632251    Free PMC article.
Adoptive Cell Therapies: Keeping Pace With New and Emerging Advances.
Patricia Mangan, Edward Stadtmauer.
J Adv Pract Oncol, 2021 Feb 19; 11(3). PMID: 33598318    Free PMC article.
Genetic engineering of T cells for immunotherapy.
Gavin I Ellis, Neil C Sheppard, James L Riley.
Nat Rev Genet, 2021 Feb 20; 22(7). PMID: 33603158    Free PMC article.
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.
David M Weiner, Joseph S Durgin, Maria Wysocka, Alain H Rook.
J Am Acad Dermatol, 2020 Dec 23; 84(3). PMID: 33352268    Free PMC article.
Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay.
Lisa Davis, Nathan Riccitelli, +6 authors, Reinhold Pollner.
Mol Ther Methods Clin Dev, 2021 Feb 23; 20. PMID: 33614827    Free PMC article.
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4.
Vijay G Bhoj, Lucy Li, +18 authors, Don L Siegel.
Mol Ther Oncolytics, 2021 Feb 23; 20. PMID: 33614919    Free PMC article.
CRISPR Takes the Front Seat in CART-Cell Development.
Claudia Manriquez-Roman, Elizabeth L Siegler, Saad S Kenderian.
BioDrugs, 2021 Feb 28; 35(2). PMID: 33638865
The Application of Nanobody in CAR-T Therapy.
Chaolemeng Bao, Quanli Gao, +7 authors, Xian-Hui Wu.
Biomolecules, 2021 Feb 12; 11(2). PMID: 33567640    Free PMC article.
Testing the Specificity of Compounds Designed to Inhibit CPT1A in T Cells.
Roddy S O'Connor, Michael C Milone.
Methods Mol Biol, 2019 Nov 30; 2097. PMID: 31776920    Free PMC article.
T cells selectively filter oscillatory signals on the minutes timescale.
Geoff P O'Donoghue, Lukasz J Bugaj, +3 authors, Wendell A Lim.
Proc Natl Acad Sci U S A, 2021 Feb 26; 118(9). PMID: 33627405    Free PMC article.
Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma.
Marcin Jasiński, Grzegorz W Basak, Wiesław W Jedrzejczak.
Front Immunol, 2021 Mar 16; 12. PMID: 33717171    Free PMC article.
Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma.
Wei Jiang, Tao Li, +9 authors, Guozhong Ji.
Front Oncol, 2021 Mar 30; 11. PMID: 33777728    Free PMC article.
Designed improvement to T-cell immunotherapy by multidimensional single cell profiling.
Irfan N Bandey, Jay R T Adolacion, +10 authors, Navin Varadarajan.
J Immunother Cancer, 2021 Mar 17; 9(3). PMID: 33722906    Free PMC article.
APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells.
Qunyi Peng, Xiongpeng Zhu, +3 authors, Shengquan Liu.
Aging (Albany NY), 2021 Mar 04; 13(5). PMID: 33653969    Free PMC article.
CAR-T cell therapy: current limitations and potential strategies.
Robert C Sterner, Rosalie M Sterner.
Blood Cancer J, 2021 Apr 08; 11(4). PMID: 33824268    Free PMC article.
CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus.
Ana Textor, Laura Grunewald, +12 authors, Annette Künkele.
Cancers (Basel), 2021 Apr 04; 13(5). PMID: 33801448    Free PMC article.
Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals.
Kento Fujiwara, Masaki Kitaura, +3 authors, Naoki Okada.
Int J Mol Sci, 2021 Apr 04; 22(5). PMID: 33804441    Free PMC article.
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia.
G Doug Myers, Michael R Verneris, Andre Goy, Richard T Maziarz.
J Immunother Cancer, 2021 Apr 14; 9(4). PMID: 33846220    Free PMC article.
CAR T-cell therapy in multiple myeloma: more room for improvement.
Phaik Ju Teoh, Wee Joo Chng.
Blood Cancer J, 2021 May 01; 11(4). PMID: 33927192    Free PMC article.
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Ying Gong, Roel G J Klein Wolterink, +2 authors, Wilfred T V Germeraad.
J Hematol Oncol, 2021 May 03; 14(1). PMID: 33933160    Free PMC article.
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Nathan Singh, Noelle V Frey, +33 authors, Marco Ruella.
Nat Med, 2021 Apr 24; 27(5). PMID: 33888899    Free PMC article.
CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.
A Stoll, H Bruns, +6 authors, D Mougiakakos.
Leukemia, 2021 May 23; 35(12). PMID: 34021248    Free PMC article.
How Can We Engineer CAR T Cells to Overcome Resistance?
Maya Glover, Stephanie Avraamides, John Maher.
Biologics, 2021 May 28; 15. PMID: 34040345    Free PMC article.
The role of small molecules in cell and gene therapy.
Lewis L Brayshaw, Carlos Martinez-Fleites, +3 authors, Christopher Herring.
RSC Med Chem, 2021 May 29; 12(3). PMID: 34046619    Free PMC article.
Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
Melanie Schwerdtfeger, Mohamed-Reda Benmebarek, +3 authors, Sebastian Kobold.
Curr Hematol Malig Rep, 2021 May 04; 16(2). PMID: 33939108    Free PMC article.
Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo.
Colby R Maldini, Daniel T Claiborne, +15 authors, Todd M Allen.
Nat Med, 2020 Sep 02; 26(11). PMID: 32868878
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development.
Kenji Hashimoto.
Cancers (Basel), 2021 Jun 03; 13(10). PMID: 34064598    Free PMC article.
Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Zhiliang Bai, Stefan Lundh, +9 authors, Rong Fan.
J Immunother Cancer, 2021 May 20; 9(5). PMID: 34006631    Free PMC article.
Immune-Based Approaches for the Treatment of Pediatric Malignancies.
Kristopher R Bosse, Robbie G Majzner, Crystal L Mackall, John M Maris.
Annu Rev Cancer Biol, 2020 Mar 01; 4. PMID: 34113750    Free PMC article.
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.
Veronika Mancikova, Michal Smida.
Int J Mol Sci, 2021 Jun 03; 22(11). PMID: 34073911    Free PMC article.
Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.
Robert D Leone, Jonathan D Powell.
Cancer Immunol Res, 2021 Mar 03; 9(3). PMID: 33648947    Free PMC article.
An Update on the HIV DNA Vaccine Strategy.
Joseph Hokello, Adhikarimayum Lakhikumar Sharma, Mudit Tyagi.
Vaccines (Basel), 2021 Jul 03; 9(6). PMID: 34198789    Free PMC article.
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.
Kathryn M Cappell, James N Kochenderfer.
Nat Rev Clin Oncol, 2021 Jul 08; 18(11). PMID: 34230645
Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents.
Chi Hoon Park.
Cancers (Basel), 2021 Jul 03; 13(13). PMID: 34209505    Free PMC article.
Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.
Saba Ghassemi, Selene Nunez-Cruz, +15 authors, Michael C Milone.
Cancer Immunol Res, 2018 Jul 22; 6(9). PMID: 30030295    Free PMC article.
Highly Cited.
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.
Cecile Geuijen, Paul Tacken, +38 authors, Mark Throsby.
Nat Commun, 2021 Jul 23; 12(1). PMID: 34290245    Free PMC article.
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
John C Flickinger, Jeffrey A Rappaport, +4 authors, Scott A Waldman.
Biomark Med, 2021 Jan 21; 15(3). PMID: 33470843    Free PMC article.
Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
Jan-Erik Meyer, Simon Loff, +6 authors, Armin Ehninger.
Oncoimmunology, 2021 Jul 23; 10(1). PMID: 34290907    Free PMC article.
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.
Noelle V Frey, Pamela A Shaw, +15 authors, David L Porter.
J Clin Oncol, 2019 Dec 10; 38(5). PMID: 31815579    Free PMC article.
Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
Stephanie Choi, Melissa A Pegues, +3 authors, James N Kochenderfer.
Hum Gene Ther, 2020 Dec 09; 32(13-14). PMID: 33287637    Free PMC article.
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients.
Luca Biasco, Natalia Izotova, +10 authors, Persis J Amrolia.
Nat Cancer, 2021 Aug 05; 2(6). PMID: 34345830    Free PMC article.
Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.
Niels W C J van de Donk, Maria Themeli, Saad Z Usmani.
Blood Cancer Discov, 2021 Aug 14; 2(4). PMID: 34386775    Free PMC article.
Single-cell imaging of T cell immunotherapy responses in vivo.
Chuan Yan, Qiqi Yang, +18 authors, David M Langenau.
J Exp Med, 2021 Aug 21; 218(10). PMID: 34415995    Free PMC article.
PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Yamin Jie, Guijun Liu, +8 authors, Anxin Gu.
Front Immunol, 2021 Sep 04; 12. PMID: 34475869    Free PMC article.
Engineering enhanced CAR T-cells for improved cancer therapy.
Michael C Milone, Jie Xu, +4 authors, J Joseph Melenhorst.
Nat Cancer, 2021 Sep 07; 2(8). PMID: 34485921    Free PMC article.
CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy.
Miriam Y Kim, Matthew L Cooper, +4 authors, John F DiPersio.
JCI Insight, 2021 Aug 24; 6(16). PMID: 34423790    Free PMC article.
Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope.
Alejandrina Hernández-López, Mario A Téllez-González, Paul Mondragón-Terán, Angélica Meneses-Acosta.
Front Pharmacol, 2021 Sep 08; 12. PMID: 34489708    Free PMC article.
CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies.
Shifaa M Abdin, Daniela Paasch, Michael Morgan, Nico Lachmann.
J Immunother Cancer, 2021 Sep 01; 9(8). PMID: 34462325    Free PMC article.
Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Hyeon Joo Yoo, Biyan Nathanael Harapan.
Immunol Res, 2021 Sep 24; 69(6). PMID: 34554405    Free PMC article.
High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms.
Radhika Thokala, Zev A Binder, +7 authors, Donald M O'Rourke.
Front Oncol, 2021 Sep 28; 11. PMID: 34568006    Free PMC article.
State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
Juliet Meir, Muhammad Abbas Abid, Muhammad Bilal Abid.
Transplant Cell Ther, 2021 Sep 30; 27(12). PMID: 34587552    Free PMC article.
Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL).
Geoffrey Shouse, Elizabeth Budde, Stephen Forman.
Cancer Treat Res, 2021 Oct 10; 181. PMID: 34626362
Improving CAR T-Cell Persistence.
Violena Pietrobon, Lauren Anne Todd, +3 authors, Francesco Marincola.
Int J Mol Sci, 2021 Oct 14; 22(19). PMID: 34639168    Free PMC article.
Programmable DNA-augmented hydrogels for controlled activation of human lymphocytes.
Alexander S Zhovmer, Morgan Chandler, +2 authors, Erdem D Tabdanov.
Nanomedicine, 2021 Jul 21; 37. PMID: 34284132    Free PMC article.
PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB "Super-Stimulation".
Gaia Zuccolotto, Alessandro Penna, +4 authors, Antonio Rosato.
Front Oncol, 2021 Oct 19; 11. PMID: 34660275    Free PMC article.
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.
Kenneth P Micklethwaite, Kavitha Gowrishankar, +17 authors, Emily Blyth.
Blood, 2021 May 12; 138(16). PMID: 33974080    Free PMC article.
Recent advances in lentiviral vectors for gene therapy.
Xiaoyu Wang, Cuicui Ma, +4 authors, Yuquan Wei.
Sci China Life Sci, 2021 Oct 29; 64(11). PMID: 34708326
Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction.
Baptiste Lamarthée, Armance Marchal, +20 authors, Julien Zuber.
Nat Commun, 2021 Nov 10; 12(1). PMID: 34750385    Free PMC article.
SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models.
Axel Hyrenius-Wittsten, Yang Su, +6 authors, Kole T Roybal.
Sci Transl Med, 2021 Apr 30; 13(591). PMID: 33910981    Free PMC article.
The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications.
Siyuan Qian, Pedro Villarejo-Campos, Damián García-Olmo.
J Clin Med, 2021 Nov 14; 10(21). PMID: 34768570    Free PMC article.
Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review.
Franziska Hauth, Alice Y Ho, Soldano Ferrone, Dan G Duda.
JAMA Oncol, 2021 Apr 23; 7(7). PMID: 33885725    Free PMC article.
T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy.
Palak H Mehta, Salvatore Fiorenza, +3 authors, Kylie M Quinn.
Front Immunol, 2021 Dec 14; 12. PMID: 34899742    Free PMC article.
Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions.
Sherien M El-Daly, Jihan Hussein.
J Appl Biomed, 2019 Mar 01; 17(1). PMID: 34907752
Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.
Melita Irving, Evripidis Lanitis, +2 authors, Sonia Guedan.
Hum Gene Ther, 2021 Oct 19; 32(19-20). PMID: 34662233    Free PMC article.
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study.
Mohsen Sheykhhasan, Hamed Manoochehri, Paola Dama.
Cancer Gene Ther, 2022 Jan 07;. PMID: 34987176
Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors.
Tamara Muliaditan, Leena Halim, +19 authors, John Maher.
Cell Rep Med, 2022 Jan 15; 2(12). PMID: 35028604    Free PMC article.
Robust T cell activation requires an eIF3-driven burst in T cell receptor translation.
Dasmanthie De Silva, Lucas Ferguson, +8 authors, Jamie Hd Cate.
Elife, 2022 Jan 01; 10. PMID: 34970966    Free PMC article.
Immunology 101: fundamental immunology for the practicing hematologist.
Shannon A Carty.
Hematology Am Soc Hematol Educ Program, 2021 Dec 11; 2021(1). PMID: 34889423    Free PMC article.
Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy.
Yan Yang, Jing Zhou, +5 authors, Qingyuan Zhang.
Transl Cancer Res, 2020 Nov 01; 9(11). PMID: 35117332    Free PMC article.
A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies.
Jia Liu, Luyao Wang, +4 authors, Leina Ma.
Transl Cancer Res, 2020 Sep 01; 9(9). PMID: 35117929    Free PMC article.
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains.
Yupanun Wutti-In, Jatuporn Sujjitjoon, +10 authors, Pa-Thai Yenchitsomanus.
Front Oncol, 2022 Feb 05; 11. PMID: 35117999    Free PMC article.
Splitting signals drives CARs further.
Tiffany R King-Peoples, Avery D Posey.
Nat Cancer, 2022 Feb 06; 2(9). PMID: 35121869
SILAC Phosphoproteomics Reveals Unique Signaling Circuits in CAR-T Cells and the Inhibition of B Cell-Activating Phosphorylation in Target Cells.
Alijah A Griffith, Kenneth P Callahan, +3 authors, Arthur R Salomon.
J Proteome Res, 2022 Jan 12; 21(2). PMID: 35014847    Free PMC article.
B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.
Shirin Teymouri Nobari, Jafar Nouri Nojadeh, Mehdi Talebi.
J Transl Med, 2022 Feb 12; 20(1). PMID: 35144648    Free PMC article.
Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?
Jochen Buechner, Ignazio Caruana, +6 authors, Friso G Calkoen.
Front Pediatr, 2022 Feb 12; 9. PMID: 35145941    Free PMC article.
T-SIGn tumor reengineering therapy and CAR T cells synergize in combination therapy to clear human lung tumor xenografts and lung metastases in NSG mice.
Olmo Sonzogni, Daniel E Zak, +6 authors, James B Rottman.
Oncoimmunology, 2022 Feb 15; 11(1). PMID: 35154906    Free PMC article.
The Hematology of Tomorrow Is Here-Preclinical Models Are Not: Cell Therapy for Hematological Malignancies.
Lorena Arranz.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35158848    Free PMC article.
Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance.
Franziska Füchsl, Angela M Krackhardt.
Cells, 2022 Feb 16; 11(3). PMID: 35159220    Free PMC article.
Rapid manufacturing of non-activated potent CAR T cells.
Saba Ghassemi, Joseph S Durgin, +13 authors, Michael C Milone.
Nat Biomed Eng, 2022 Feb 23; 6(2). PMID: 35190680    Free PMC article.
Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
Sakiko Harada, Miki Ando, +15 authors, Norio Komatsu.
Mol Ther, 2021 Oct 11; 30(2). PMID: 34628050    Free PMC article.
The Role of Bispecific Antibodies in Non-Hodgkin's Lymphoma: From Structure to Prospective Clinical Use.
Rita Tavarozzi, Enrica Manzato.
Antibodies (Basel), 2022 Mar 01; 11(1). PMID: 35225874    Free PMC article.
Genetic Modification of T Cells for the Immunotherapy of Cancer.
Suzanne Quinn, Natasha Lenart, +3 authors, Michael I Nishimura.
Vaccines (Basel), 2022 Mar 27; 10(3). PMID: 35335089    Free PMC article.
CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers.
Chuan Jin, Jing Ma, +2 authors, Magnus Essand.
Nat Biomed Eng, 2022 Apr 06;. PMID: 35379957
CAR-T cell therapy for lung cancer: Potential and perspective.
Long Chen, Fukun Chen, +5 authors, Yunchao Huang.
Thorac Cancer, 2022 Mar 16; 13(7). PMID: 35289077    Free PMC article.
Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients.
Maria-Luisa Schubert, Carolina Berger, +14 authors, Boris Fehse.
Int J Oncol, 2022 Mar 17; 60(5). PMID: 35294040    Free PMC article.
Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.
Siyuan Qian, Pedro Villarejo-Campos, +6 authors, Cheng Qian.
Front Immunol, 2022 Apr 12; 13. PMID: 35401510    Free PMC article.
Minimally Invasive Preclinical Monitoring of the Peritoneal Cavity Tumor Microenvironment.
Zachary Spencer Dunn, Yan-Ruide Li, +10 authors, Lili Yang.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406547    Free PMC article.
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells.
Julie O'Neal, Julie K Ritchey, +14 authors, John F DiPersio.
Leukemia, 2022 Apr 16; 36(6). PMID: 35422095
RNA polymerase II pausing factor NELF in CD8+ T cells promotes antitumor immunity.
Bogang Wu, Xiaowen Zhang, +10 authors, Rong Li.
Nat Commun, 2022 Apr 22; 13(1). PMID: 35444206    Free PMC article.
Development of CAR T Cell Therapy in Children-A Comprehensive Overview.
Michael Boettcher, Alexander Joechner, +2 authors, Patrick Schlegel.
J Clin Med, 2022 Apr 24; 11(8). PMID: 35456250    Free PMC article.
Nanobody-based CAR-T cells for cancer immunotherapy.
Pouya Safarzadeh Kozani, Abdolhossein Naseri, +4 authors, Pooria Safarzadeh Kozani.
Biomark Res, 2022 Apr 27; 10(1). PMID: 35468841    Free PMC article.
Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.
Zhitao Ying, Yuqin Song, Jun Zhu.
Front Pharmacol, 2022 May 14; 13. PMID: 35548364    Free PMC article.
Systematic Review.
A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia.
Qian Zhang, Morgan E Hresko, +8 authors, Michael C Milone.
Sci Transl Med, 2021 Dec 23; 13(625). PMID: 34936380    Free PMC article.